UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM ~~10-Q~~10-Q/A

(Amendment No. 1)

~~[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934~~

~~For the quarterly period ended~~~~September 30, 2019~~

~~[ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934~~

~~For the transition period from __________ to __________~~

[X]	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2020

OR

[ ]	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

Commission File No.~~1-38148~~001-38148

~~CO-DIAGNOSTICS, INC~~.

~~(Exact Name of Registrant as Specified in Its Charter)~~

CO-DIAGNOSTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Utah

46-2609396

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address of principal executive offices and zip code)

(801) 438-1036

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the ~~Act.~~Act:

Title of each class		~~Ticker Symbol~~ Trading Symbol(s)		Name of each exchange on which registered
Common ~~stock,~~Stock, par value $0.001 per share		CODX		~~Nasdaq Capital Market~~NASDAQ-CM

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[ ]X]	Smaller reporting company	[X]
		Emerging growth company	[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

~~There~~As of August 12, 2020, there were ~~17,339,922~~28,082,709 shares of the Registrant’s ~~$0.001~~common stock, par value ~~common stock outstanding as of November 8, 2019.~~$0.001 per share, outstanding.

Explanatory Note

We are filing this Amendment No. 1 on Form 10Q/A (“Amended Report”) to amend our Quarterly Report for the quarter ended June 30, 2020, that was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 13, 2020 (the “Original Report”), to restate our condensed consolidated financial statements for the period ended June 30, 2020. Consequently, the previously filed unaudited condensed consolidated financial statements for the period ended June 30, 2020, should no longer be relied upon.

In accordance with applicable SEC rules, this Amended Report also includes new certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, as amended, from our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) dated November 3, 2020 10-Q as of the filing date of this Amended Report.

Amendment and Restatement Background

As previously disclosed in a Current Report on Form 8-K filed with the SEC on November 2, 2020, the Board of Directors of Co-Diagnostics, Inc. (the “Company”) and executive management determined, in consultation with the Company’s independent public accounting firm, Haynie & Company, that the Company’s condensed consolidated interim financial statements (unaudited) for the quarterly period ended June 30, 2020 included in the Original Filing could no longer be relied upon as the Original Report contained a material error. Specifically, during the course of the financial statements closing process subsequent to the period ended June 30, 2020, the Company’s CEO and CFO (collectively, “the Management”) discovered that a prepayment for inventory received after June 30, 2020 was incorrectly recorded as cost of revenue instead of as a prepaid expense in the Company’s Original Filing.

This error resulted in prepaid expenses, gross profit, and net income being understated by $2,369,369 and cost of revenue being overstated by $2,369,369 in the Original Filing. With this error being corrected in this Amended Report, gross profit and net income increased by $2,369,369. Additionally, the change resulted in an increase of basic and diluted net income per common share of $0.08. See Note 3 to the amended and restated condensed consolidated interim financial statements (unaudited) included in this Amended Report.

Because these revisions are treated as corrections of errors to our prior period financial results, the revisions are considered to be an “amendment” under U.S. generally accepted accounting principles (“GAAP”). Accordingly, the revised financial information included in this Amended Report has been identified as “amended and restated”.

Items Amended in this Amendment

The following sections in the Original Filing are revised in this Amended Report, solely as a result of, and to reflect, the restatement:

	●	Part I – Item 1. Financial Information
	●	Part I – Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
	●	Part I – Item 4. Controls and Procedures
	●	Part II – Item 6. Exhibits and Signatures

For the convenience of the reader, this Amended Report sets forth the information in the Original Filing in its entirety, as such information is modified and superseded where necessary to reflect the restatements. This Amended Report does not amend, update or change any other items or disclosures in the Original Filing and does not purport to reflect any information or events subsequent to the filing thereof. As such, this Amended Report speaks only as of the filing date of the Original Filing, and the Company has not undertaken herein to amend, supplement or update any information contained in the Original Filing to give effect to any subsequent events. Accordingly, this Amended Report should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Filing, including any amendment to those filings.

Co-Diagnostics, Inc.

Form 10-Q

PART I FINANCIAL INFORMATION:

Item 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets as of ~~September~~June 30, ~~2019~~2020 and December 31, ~~2018~~2019 (unaudited)	3

	Condensed Consolidated Statements of Operations for the Three and ~~Nine~~Six Months Ended ~~September~~June 30, 2020 and 2019 ~~and 2018~~ (unaudited)	4

	Condensed Consolidated Statements of Cash Flows for the ~~Nine~~Six Months Ended ~~September~~June 30, 2020 and 2019 ~~and 2018~~ (unaudited)	5

	Condensed Consolidated Statements of Stockholders’ Equity (unaudited)	6

	Notes to Condensed Consolidated Financial Statements (unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1418

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2131

Item 4.	Controls and Procedures	2131

PART II OTHER INFORMATION:

Item 1.	Legal Proceedings	2231

Item 1A.	Risk Factors	2232

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2235

Item 3.	Defaults Upon Senior Securities	2236

Item 4.	Mine Safety Disclosures	2236

Item 5.	Other Information	2236

Item 6.	Exhibits	2236

	Signatures	2337

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CO – DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, 2019 December 31, 2018
ASSETS:
Current Assets
Cash and cash equivalents $ 2,544,159 $ 950,237
Accounts receivables, net 60,353 13,420
Inventory 17,353 18,153
Prepaid expenses 462,583 70,103
Total current assets 3,084,448 1,051,913
Other Assets
Property and equipment, net 179,746 156,138
Investment in joint venture 547,685 345,121
Total other assets 727,431 501,259

Total assets $ 3,811,879 $ 1,553,172

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT):

Current Liabilities
Accounts payable $ 21,760 $ 148,967
Accrued expenses 161,738 174,444
Accrued expenses (related party) 120,000 120,000
Deferred income 4,386 —
Notes payable net of discount of $0 and $91,428 — 1,908,572
Total current liabilities 307,884 2,351,983
Long-term Liabilities, net of current portion
Accrued expenses-long-term (related party) 170,000 260,000
Total long-term liabilities, net of current portion 170,000 260,000
Total liabilities 477,884 2,611,983

Commitments and contingencies

STOCKHOLDERS’ EQUITY (DEFICIT):
Convertible preferred stock, $.001 par value; 5,000,000 shares authorized, 25,600 and no shares issued and outstanding, respectively 26 —

Common stock, $.001 par value, 100,000,000 shares authorized; 17,336,922 and 12,923,383 shares issued and outstanding, respectively. 17,337 12,923
Additional paid-in capital 26,471,376 17,622,433
Accumulated deficit (23,154,718 ) (18,694,167 )
Total stockholders’ equity (deficit) 3,333,995 (1,058,811 )

Total liabilities and stockholders’ equity (deficit) $ 3,811,879 $ 1,553,172

	June 30, 2020			December 31, 2019
	Restated
Assets
Current assets
Cash and cash equivalents	$	18,550,437		$	893,138
Accounts receivable, net		5,349,876			131,382
Inventory		10,110,786			197,168
Prepaid expenses		2,890,549			362,566
Total current assets		36,901,648			1,584,254
Property and equipment, net		473,376			196,832
Investment in joint venture		1,416,480			434,240
Total assets	$	38,791,504		$	2,215,326
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	1,127,709		$	5,959
Accrued expenses		691,385			200,788
Accrued expenses (related party)		120,000			120,000
Deferred revenue		1,045,548			1,323
Total current liabilities		2,984,642	��		328,070
Accrued expenses-long-term (related party)		80,000			150,000
Total liabilities		3,064,642			478,070
Commitments and contingencies (Note 1)
Stockholders’ equity
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 25,600 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively		-			26
Common Stock, $0.001 par value; 100,000,000 shares authorized; 27,991,042 and 17,342,922 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively		27,991			17,343
Additional paid-in capital		46,726,869			26,687,701
Accumulated deficit		(11,027,998	)		(24,967,814	)
Total stockholders’ equity		35,726,862			1,737,256
Total liabilities and stockholders’ equity	$	38,791,504		$	2,215,326

See accompanying notes to unaudited condensed consolidated financial ~~statements.~~statements

CO – DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

For the Three Months
Ended September 30, For the Nine Months
Ended September 30,
2019 2018 2019 2018
Net sales $ 41,434 $ 9,696 $ 106,408 $ 29,088
Cost of sales 20,365 — 59,626 —
Gross profit 21,069 9,696 46,782 29,088
Operating expenses:
Sales and marketing 262,360 180,257 770,539 419,410
Administrative and general 1,060,763 1,150,170 2,508,895 2,880,884
Research and development 331,027 330,422 990,923 985,726
Depreciation and amortization 17,006 12,616 46,768 37,634
Total operating expenses 1,671,156 1,673,465 4,317,125 4,323,654
Loss from operations (1,650,087 ) (1,663,769 ) (4,270,343 ) (4,294,566 )
Other expense:
Interest income 12,207 3,520 32,255 17,361
Interest expense (10 ) (48,857 ) (106,437 ) (48,857 )
Gain on disposition of assets — — 850 —
Gain (loss) on equity method investment in joint venture (109,876 ) 67,961 (116,876 ) 2,507
Total other expense (97,679 ) 22,624 (190,208 ) (28,989 )
Loss before income taxes (1,747,766 ) (1,641,145 ) (4,460,551 ) (4,323,555 )
Provision for income taxes — — — —
Net loss $ (1,747,766 ) $ (1,641,145 ) $ (4,460,551 ) $ (4,323,555 )

Basic and diluted income (loss) per common share $ (0.10 ) $ (0.13 ) $ (0.27 ) $ (0.35 )

Weighted average common shares outstanding, basic and diluted 17,328,787 12,326,316 16,809,085 12,341,482
Three Months Ended
June 30, 2020 Six Months Ended
June 30, 2020
2020 2019 2020 2019
(Restated) (Restated)
Net revenue $ 24,040,274 $ 61,574 $ 25,588,802 $ 64,974
Cost of revenue 5,975,305 38,809 6,457,045 39,261
Gross profit 18,064,969 22,765 19,131,757 25,713
Operating expenses
Sales and marketing 390,191 252,076 658,674 508,179
Administrative and general 2,191,034 807,769 3,650,518 1,448,132
Research and development 750,249 312,590 1,150,271 659,896
Depreciation and amortization 25,218 16,094 45,966 29,762
Total operating expenses 3,356,692 1,388,529 5,505,429 2,645,969
Income (loss) from operations 14,708,277 (1,365,764 ) 13,626,328 (2,620,256 )
Other income (expense)
Interest income 38,173 19,640 45,748 20,048
Interest expense - - - (106,427 )
Gain on disposition of assets - - - 850
Gain (loss) on equity method investment in joint venture 258,559 1,728 267,740 (7,000 )
Total other income (expense) 296,732 21,368 313,488 (92,529 )
Income (loss) before income taxes 15,005,009 (1,344,396 ) 13,939,816 (2,712,785 )
Provision for income taxes - - - -
Net income (loss) $ 15,005,009 $ (1,344,396 ) $ 13,939,816 $ (2,712,785 )
Net income (loss) per common share:
Basic $ 0.54 $ (0.08 ) $ 0.50 $ (0.16 )
Diluted $ 0.51 $ (0.08 ) $ 0.48 $ (0.16 )
Weighted average shares outstanding:
Basic 27,582,229 17,017,964 27,605,137 17,017,964
Diluted 29,152,222 17,017,964 29,094,475 17,017,964

See accompanying notes to unaudited condensed consolidated financial ~~statements.~~statements

4

CO – DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

Nine Months Ended
September 30,

2019 2018
Cash flows from operating activities:
Net loss $ (4,460,551 ) $ (4,323,555 )
Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 46,768 37,634
Stock based compensation 570,632 570,385
Accretion of notes payable discount 91,428 —
Gain on disposition of assets (850 ) —
Loss (gain) of equity method investment 116,876 (2,507 )
Changes in assets and liabilities:
Increase in accounts and other receivables (39,433 ) —
Increase (decrease) in deferred income 4,386 (29,088 )
(Increase) decrease in prepaid and other assets (12,993 ) 694,036
Decrease in inventory 800 —
Decrease in accounts payable and accrued expenses (229,913 ) (66,306 )

Net cash used in operating activities (3,912,850 ) (3,119,401 )

Cash flows from investing activities:
Purchase of property and equipment (77,026 ) (2,500 )
Investment in joint venture (319,440 ) (135,000 )

Net cash used by investing activities (396,466 ) (137,500 )

Cash flows from financing activities:
Proceeds from sale of common stock 5,496,002 30,000
Proceeds from sale of preferred stock 1,000,000 —
Proceeds from the issuance of debt — 2,000,000
Payment of offering costs (592,764 ) (130,988 )

Net cash provided by financing activities 5,903,238 1,899,012

Net increase (decrease) in cash 1,593,922 (1,357,889 )

Cash and cash equivalents beginning of period 950,237 3,534,454

Cash and cash equivalents end of period $ 2,544,159 $ 2,176,565

Supplemental disclosure of cash flow information:
Interest paid $ 15,000 $ 26,000
Income taxes paid $ — $ —
Schedule of non-cash investing and financing activities:
Warrants issued for services $ 379,487 —
Conversion of preferred stock to common $ 440,000 $ —
Conversion of debt for preferred stock $ 2,000,000 $ —
Six Months Ended June 30,
2020 2019
(Restated)
Cash flows from operating activities
Net income (loss) $ 13,939,816 $ (2,712,785 )
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation and amortization 45,966 29,762
Stock-based compensation expense 1,124,242 294,677
Accretion of notes payable discount - 91,428
Gain on disposition of assets - (850 )
Loss (gain) from equity method investment (267,740 ) 7,000
Changes in assets and liabilities:
Accounts and other receivable (5,218,494 ) (42,065 )
Prepaid and other assets (2,527,983 ) (183,446 )
Inventory (10,030,838 ) 9,920
Deffered revenue 1,044,225 -
Accounts payable and accrued expenses 1,542,347 (191,332 )
Net cash used in operating activities (348,459 ) (2,697,691 )
Cash flows from investing activities
Purchase of property and equipment (205,290 ) (52,775 )
Investment in joint venture (714,500 ) (247,000 )
Net cash used in investing activities (919,790 ) (299,775 )
Cash flows from financing activities
Proceeds from sale of common stock 19,470,005 5,496,002
Proceeds from sale of preferred stock - 1,000,000
Proceeds from exercise of options and warrants 913,465 -
Payment of offering costs (1,457,922 ) (592,764 )
Net cash provided by financing activities 18,925,548 5,903,238
Net increase in cash and cash equivalents 17,657,299 2,905,772
Cash and cash equivalents at beginning of period 893,138 950,237
Cash and cash equivalents at end of period $ 18,550,437 $ 3,856,009
Supplemental disclosure of cash flow information
Interest paid $ - $ 15,000
Income taxes paid $ - $ -
Supplemental disclosure of non-cash investing and financing transactions
Inventory moved to property, plant and equipment $ 117,220 $ -

See accompanying notes to unaudited condensed consolidated financial ~~statements.~~statements

5

CO – DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
For the Six Months ending June 30, 2020 (Restated) and 2019
(Unaudited)

Convertible
Preferred Stock Common Stock Additional
Paid-In- Accumulated
Total
Stockholders’
Equity
Convertible Preferred Stock Common Stock Additional Paid-in Accumulated Total Stockholders’
Shares Amount Shares Amount Capital Deficit Equity
Balance as of December 31, 2019 25,600 $ 26 17,342,922 $ 17,343 $ 26,687,701 $ (24,967,814 ) $ 1,737,230
Public offering, net of offering costs of $1,457,922 - - 7,242,954 7,243 18,004,840 - 18,012,083
Issuance of common stock for warrant exercises - - 719,492 720 49,280 - 50,000
Stock-based compensation expense - - 12,363 12 432,811 - 432,823
Conversion of preferred stock to common (25,600 ) (26 ) 2,133,333 2,133 (2,107 ) - -
Net loss - - - - - (1,065,193 ) (1,065,193 )
Balance as of March 31, 2020 - $ - 27,451,064 $ 27,451 $ 45,172,525 $ (26,033,007 ) $ 19,166,943
Issuance of common stock for warrant exercises - - 530,289 530 862,935 - 863,465
Stock-based compensation expense - - 9,689 10 691,409 - 691,419
Net income - - - - - 15,005,009 15,005,009
Balance as of June 30, 2020 - $ - 27,991,042 $ 27,991 $ 46,726,869 $ (11,027,998 ) $ 35,726,836
Shares Amount Shares Amount Capital Deficit (Deficit)
Balance as of December 31, 2018     — $         — 12,923,383 $ 12,923 $ 17,622,433 $ (18,694,167 ) $ (1,058,811 ) - $ - 12,923,383 $ 12,923 $ 17,622,433 $ (18,694,167 ) $ (1,058,811 )
Public offering, net of offering costs of $592,764 — — 3,925,716 3,926 4,899,312 — 4,903,238 - - 3,925,716 3,926 4,899,312 - 4,903,238
Issuance of Preferred Stock 30,000 30 — — 2,999,970 — 3,000,000
Issuance of preferred stock 30,000 30 - - 2,999,970 - 3,000,000
Stock-based compensation expense — — — — 87,794 — 87,794 - - - - 87,794 - 87,794
Conversion of Preferred Stock to Common (2,000 ) (2 ) 166,667 167 (165 ) — —
Conversion of preferred stock to common (2,000 ) (2 ) 166,667 167 (165 ) - -
Net loss — — — — — (1,368,389 ) (1,368,389 ) - - - - - (1,368,389 ) (1,368,389 )
Balance as of March 31, 2019 28,000 $ 28 17,015,766 $ 17,016 $ 25,609,344 $ (20,062,556 ) $ 5,563,832 28,000 $ 28 17,015,766 $ 17,016 $ 25,609,344 $ (20,062,556 ) $ 5,563,832

Stock-based compensation — — — — 505,970 — 505,970
Stock-based compensation expense - - - - 505,970 - 505,970
Issuance of common stock for services — 100,000 100 80,300 80,400 - - 100,000 100 80,300 - 80,400
Net loss — — — — — (1,344,396 ) (1,344,396 ) - - - - - (1,344,396 ) (1,344,396 )
Balance as of June 30, 2019 28,000 $ 28 17,115,766 $ 17,116 $ 26,195,614 $ (21,406,952 ) $ 4,805,806 28,000 $ 28 17,115,766 $ 17,116 $ 26,195,614 $ (21,406,952 ) $ 4,805,806

Stock-based compensation — — — — 253,798 — 253,798
Issuance of common stock for services — 21,156 21 22,136 — 22,157
Conversion of Preferred Stock to Common (2,400 ) (2 ) 200,000 200 (198 ) — —
Net loss — — — — — (1,747,766 ) (1,747,766 )
Balance as of September 30, 2019 25,600 $ 26 17,336,922 $ 17,337 $ 26,471,350 $ (23,154,718 ) $ 3,333,995

Convertible
Preferred Stock
Common Stock Additional
Paid-In- Accumulated
Total
Stockholders’
Equity

Shares Amount Shares Amount Capital Deficit (Deficit)

Balance as of December 31, 2017      — $        — 12,317,184 $ 12,317 $ 16,260,651 (12,422,444 ) 3,850,524
Issuance of Common Stock for Services — — 9,225 9 24,991 — 25,000
Net loss — — — — (1,310,233 ) (1,310,233 )
Balance as of March 31, 2018 — $ — 12,326,409 $ 12,326 $ 16,285,642 $ (13,732,677 ) $ 2,565,291

Stock-based compensation — — 21,618 22 49,978 — 50,000

Net loss — — — — — (1,372,177 ) (1,372,177 )
Balance as of June 30, 2018 — $ — 12,348,027 $ 12,348 $ 16,335,620 $ (15,104,854 ) $ 1,243,114

Stock-based compensation — — 316,996 317 525,068 — 525,385

Net loss — — — — — (1,641,145 ) (1,641,145 )
Balance as of September 30, 2018 — $ — 12,665,023 $ 12,665 $ 16,860,688 $ (16,745,999 ) $ 127,354
See accompanying notes to unaudited condensed consolidated financial ~~statements.~~statements

6

CO – DIAGNOSTICS, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~September~~June 30, ~~2019~~2020
(Unaudited)

~~Note~~NOTE 1 ~~- Basis of Presentation~~– OVERVIEW AND BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the ~~three~~six and ~~nine-month~~three-month periods ended ~~September~~June 30, ~~2019~~2020 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2019.~~2020. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, ~~2018,~~2019, included in the Company’s Annual Report on Form 10-K filed on March ~~28, 2019.~~30, 2020.
Certain 2019 financial statement amounts have been reclassified to conform to 2020 presentations.

Description of Business

Co-Diagnostics, Inc. ~~(“we,” “our,” or the “Company”)~~, a Utah corporation ~~headquartered in Salt Lake City, Utah,~~(the “Company” or “CDI”), is adeveloping robust and innovative molecular ~~diagnostics company formed in April 2013~~tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. We have developed and we manufacture and sell reagents used for diagnostic tests that ~~develops, manufactures and markets a new, state-of-the-art diagnostics technology.~~function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”).

Ourdiagnostics systems ~~are designed to~~ enable very rapid, low-cost, ~~sophisticated~~ molecular testing for organisms and genetic diseases by ~~greatly~~ automating historically complex procedures in both the development and administration of tests. ~~Our newest~~CDI’s technical advance involves a novel approach to Polymerase Chain Reaction (“PCR”) test design of primer ~~design (CoPrimers™~~and probe structure (“CoPrimers”) that eliminates one of the key vexing issues of PCR amplification, the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA. In addition, our scientists have enhanced the understanding of the mathematics of DNA test design, so as to “engineer” a DNA test and automate algorithms to screen millions of possible designs to optimize DNA test design. Our proprietary platform of Co-Dx™ technologies integrates and streamlines these steps as it analyzes biological samples.

Our portfolio of molecular diagnostics development products and tests represents a new advancement in the understanding of the molecular interactions of DNA. The Company uses highly specialized, proprietary cooperative-theory mathematics that may lead to a revolutionary leap forward in the detection of infectious diseases, genetic disorders and other conditions. CoDx™ tests are a fraction of the cost of other DNA-based tests, designed for a new generation of affordable, mobile point-of-care diagnostic devices and compatible with many other devices, creating opportunities for state-of-the-art diagnostics available anywhere in the world, including developing countries.
7

~~Recent Accounting Pronouncements~~
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.
The Company, an emerging growth company (“EGC”), has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to clarify guidance on the presentation and classification of certain cash receipts and payments in the statement of cash flows. This update was issued with the intent of reducing diversity in practice with respect to eight types of cash flows. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, for public EGC companies like us. The update did not have a significant impact on the Company’s financial statements.
In February 2016, the FASB issued ASU No. 2016-02 Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2019, for public EGC companies like us. Management is currently evaluating the impact that the updated standard will have on its consolidated financial statements and related disclosures.
In May 2014, the FASB issued ASU No. 2014-09: “Revenue from Contracts with Customers (Topic 606)” which supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition”, and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additional revenue recognition updates were also issued in 2016 and 2017, which further clarified certain aspects of the new revenue recognition guidance. The new authoritative guidance is effective for interim and annual periods beginning after December 15, 2018, for public EGC companies like us. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (the full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company adopted the modified retrospective method. The update did not have a significant impact on the Company’s financial statements.
~~Note 2 - Significant Accounting Policies~~
~~Earnings (Loss) per Share~~
Basic earnings or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period. As the Company experienced net losses during the three and nine months ended September 30, 2019, and 2018, respectively, no common stock equivalents have been included in the diluted earnings per common share calculations as the effect of such common stock equivalents would be anti-dilutive. For the three and nine months ended September 30, 2019, there were 5,108,685 potentially dilutive shares consisting of; (i) 2,021,817 outstanding options, (ii) 953,535 outstanding warrants and (iii) 2,133,333 for issued and outstanding convertible preferred stock. For the three and nine months ended September, 30, 2018, there were 1,606,242 potentially dilutive shares consisting of 1,172,707 outstanding options and 433,535 outstanding warrants.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

NOTE 2 – SUMMARY of SIGNIFICANT ACCOUNTING POLICIES
Accounts Receivable
Trade accounts receivable are ~~carried~~recorded at ~~original invoice~~the invoiced amount ~~less~~(net of allowance) and do not bear interest. The Company maintains an ~~estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Management determines the~~ allowance for doubtful accounts ~~by identifying troubled accounts~~for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and ~~by using historical experience applied to an aging of accounts. Trade receivables~~current payment patterns. Account balances are written off ~~when~~against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At ~~September~~June 30, ~~2019~~2020 total accounts receivable was ~~$77,676~~$5,885,065 with an allowance for uncollectable accounts of ~~$17,323~~$535,389 resulting in a net amount of ~~$60,353.~~$5,349,876.

Equity-Method Investments

Our equity method investments are initially recorded at costs and are included in other long-term assets in the accompanying condensed consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other ~~losses~~expense in the accompanying condensed consolidated statements of operations.
Inventory
Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At June 30, 2020, we had $10,110,786 in inventory of which $3,763,472 was finished goods and $6,347,314 was raw materials. Provisions are made to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values. The Company establishes reserves for this purpose.

8

~~Note 3 – Going Concern~~Revenue Recognition

The ~~accompanying~~Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.
The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.
Earnings (Loss) per Share
Basic earnings or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period. For the three and six months ended June 30, 2020 the Company included 1,401,561 and 87,777, and 1,493,821 and 76,172 for outstanding options and warrants, respectively in calculating the diluted earnings per share. As the Company experienced net losses during the three and six months ended June 30, 2019, respectively, no common stock equivalents have been included in the diluted earnings per common share calculations as the effect of such common stock equivalents would be anti-dilutive. For the three and six months ended June 30, 2019, there were 4,534,575 potentially dilutive shares consisting of: (i) 1,247,707 for outstanding options, (ii) 953,535 for outstanding warrants and (iii) 2,333,333 for issued and outstanding shares of convertible preferred stock.
Research and Development
Research and development costs are expensed when incurred. The Company expensed $750,249 and $1,150,271 of research and development costs for the three and six months ended June 30, 2020, respectively. The Company expensed $312,590 and $659,896 of research and development costs for the three and six months ended June 30, 2019, respectively.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.
As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2020, for public EGC companies like us. The Company expects to use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company expects its balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheet, but does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13, which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us, but the Company may adopt upon election, it on January 1, 2021. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) (“ASU 2019-12”), which removes certain exceptions for investments, intraperiod allocations and interim calculations and adds guidance to reduce complexity in accounting for income taxes. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020; early adoption is permitted. The Company is still assessing the amendments of ASU 2019-12 and the impact the amendments will have on the Company’s consolidated financial statements ~~have been prepared on a going concern basis, which contemplates the realization of assets~~ and ~~the satisfaction of liabilities~~related disclosures.
Commitments and Contingency
On July 16, 2020, we were served in an action filed in the ~~normal course~~United States District Court for the District of ~~business.~~Utah claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The Plaintiff, Gelt Trading, Ltd., a Cayman Islands limited company, demands compensatory damages sustained as a result of our alleged wrongdoing in an amount to be proven at trial. We will vigorously defend this action as we do not believe it has any merit.
In addition, there is a threatened lawsuit from former consultants claiming compensation for services rendered in 2015. We will vigorously defend this matter if it results in a lawsuit.
9
NOTE 3 – RESTATEMENT OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Subsequent to the filing of its Form 10-Q on August 13, 2020, the Company identified an accounting issue relating to an understatement of prepaid inventory and an overstatement of cost of revenue during the three and six months ended June 30, 2020. The Company ~~has incurred losses~~evaluated the error and ~~has not demonstrated~~determined that the ~~ability to generate sufficient cash flows from operations to satisfy our liabilities~~change resulting in an increase of prepaid expenses, gross profit, and ~~sustain operations. These factors raise substantial doubt about our ability to continue as~~net income of $2,369,369 and a ~~going concern.~~decrease of cost of revenue and accumulated deficit of $2,369,369. Additionally, the change resulted in an increase of net income per common share for basic and diluted of $0.08.

~~We experienced negative cash flow used~~As a result, the Company restated its previously issued unaudited consolidated financial statements, included in ~~operations during~~its Amendment to the ~~nine~~Company’s Quarterly Report on Form 10-Q/A for the three and six months ~~ending September~~ended June 30, ~~2019~~2020, filed on August 13, 2020.
The following tables present the effects of ~~$3,912,850 compared to negative cash flow used in~~the restatement on the Company’s condensed consolidated balance sheet as of June 30, 2020, the condensed consolidated statements of operations for the ~~nine~~three and six months ended ~~September~~June 30, ~~2018~~2020 and the condensed consolidated cash flows for the six months ended June 30, 2020. In addition to the tables presented below, the Company’s accumulated deficit per the condensed consolidated statements of ~~$3,119,401.~~stockholders’ equity as of June 30, 2020 decreased from ($13,397,367) to ($11,027,998) as a result of the increase in net income from $12,635,640 to $15,005,009 for the three months ended June 30, 2020.
10
Condensed Consolidated Balance Sheet
June 30, 2020
As Previously Reported Adjustments As Restated

Assets
Current assets
Cash and cash equivalents $ 18,550,437 $ - $ 18,550,437
Accounts receivable, net 5,349,876 - 5,349,876
Inventory 10,110,786 - 10,110,786
Prepaid expenses 521,180 2,369,369 2,890,549
Total current assets 34,532,279 2,369,369 36,901,648
Property and equipment, net 473,376 - 473,376
Investment in joint venture 1,416,480 - 1,416,480
Total assets $ 36,422,135 $ 2,369,369 $ 38,791,504
Liabilities and stockholders’ equity
Current liabilities
Accounts payable $ 1,127,709 $ - $ 1,127,709
Accrued expenses 691,385 - 691,385
Accrued expenses (related party) 120,000 - 120,000
Deferred revenue 1,045,548 - 1,045,548
Total current liabilities 2,984,642 - 2,984,642
Accrued expenses-long-term (related party) 80,000 - 80,000
Total liabilities 3,064,642 - 3,064,642
Commitments and contingencies (Note 1)
Stockholders’ equity
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 25,600 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively - - -
Common Stock, $0.001 par value; 100,000,000 shares authorized; 27,991,042 and 17,342,922 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively 27,991 - 27,991
Additional paid-in capital 46,726,869 - 46,726,869
Accumulated deficit (13,397,367 ) 2,369,369 (11,027,998 )
Total stockholders’ equity 33,357,493 2,369,369 35,726,862
Total liabilities and stockholders’ equity $ 36,422,135 $ 2,369,369 $ 38,791,504
11
Condensed Consolidated Statement of Operations
Three Months Ended June 30, 2020
As Previously Reported Adjustments As Restated

Net revenue $ 24,040,274 $ - $ 24,040,274
Cost of revenue 8,344,674 (2,369,369 ) 5,975,305
Gross profit 15,695,600 2,369,369 18,064,969
Operating expenses
Sales and marketing 390,191 - 390,191
Administrative and general 2,191,034 - 2,191,034
Research and development 750,249 - 750,249
Depreciation and amortization 25,218 - 25,218
Total operating expenses 3,356,692 - 3,356,692
Income from operations 12,338,908 2,369,369 14,708,277
Other income
Interest income 38,173 - 38,173
Interest expense - - -
Gain on disposition of assets - - -
Gain (loss) on equity method investment in joint venture 258,559 - 258,559
Total other income 296,732 - 296,732
Income before income taxes 12,635,640 2,369,369 15,005,009
Provision for income taxes - - -
Net income $ 12,635,640 $ 2,369,369 $ 15,005,009
Net income per common share:
Basic $ 0.46 $ 0.08 $ 0.54
Diluted $ 0.43 $ 0.08 $ 0.51
Weighted average shares outstanding:
Basic 27,582,229 27,582,229 27,582,229
Diluted 29,152,222 29,152,222 29,152,222
12
Condensed Consolidated Statement of Operations
Six Months Ended June 30, 2020
As Previously Reported Adjustments As Restated

Net revenue $ 25,588,802 $ - $ 25,588,802
Cost of revenue 8,826,414 (2,369,369 ) 6,457,045
Gross profit 16,762,388 2,369,369 19,131,757
Operating expenses
Sales and marketing 658,674 - 658,674
Administrative and general 3,650,518 - 3,650,518
Research and development 1,150,271 - 1,150,271
Depreciation and amortization 45,966 - 45,966
Total operating expenses 5,505,429 - 5,505,429
Income (loss) from operations 11,256,959 2,369,369 13,626,328
Other income
Interest income 45,748 - 45,748
Interest expense - - -
Gain on disposition of assets - - -
Gain (loss) on equity method investment in joint venture 267,740 - 267,740
Total other income 313,488 - 313,488
Income before income taxes 11,570,447 2,369,369 13,939,816
Provision for income taxes - - -
Net income $ 11,570,447 $ 2,369,369 $ 13,939,816
Net income per common share:
Basic $ 0.42 $ 0.08 $ 0.50
Diluted $ 0.40 $ 0.08 $ 0.48
Weighted average shares outstanding:
Basic 27,605,137 27,605,137 27,605,137
Diluted 29,094,475 29,094,475 29,094,475
13
Condensed Consolidated Statement of Cash Flows
Six Months Ended June 30, 2020
As Previously Reported Adjustments As Restated
Cash flows from operating activities
Net income $ 11,570,447 $ 2,369,369 $ 13,939,816
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation and amortization 45,966 - 45,966
Stock-based compensation expense 1,124,242 - 1,124,242
Accretion of notes payable discount - - -
Gain on disposition of assets - - -
Loss (gain) from equity method investment (267,740 ) - (267,740 )
Changes in assets and liabilities:
Accounts and other receivable (5,218,494 ) - (5,218,494 )
Prepaid and other assets (158,614 ) (2,369,369 ) (2,527,983 )
Inventory (10,030,838 ) - (10,030,838 )
Deffered revenue 1,044,225 - 1,044,225
Accounts payable and accrued expenses 1,542,347 - 1,542,347
Net cash used in operating activities (348,459 ) - (348,459 )
Cash flows from investing activities
Purchase of property and equipment (205,290 ) - (205,290 )
Investment in joint venture (714,500 ) - (714,500 )
Net cash used in investing activities (919,790 ) - (919,790 )
Cash flows from financing activities
Proceeds from sale of common stock 19,470,005 - 19,470,005
Proceeds from sale of preferred stock - - -
Proceeds from exercise of options and warrants 913,465 - 913,465
Payment of offering costs (1,457,922 ) - (1,457,922 )
Net cash provided by financing activities 18,925,548 - 18,925,548
Net increase in cash and cash equivalents 17,657,299 - 17,657,299
Cash and cash equivalents at beginning of period 893,138 - 893,138
Cash and cash equivalents at end of period $ 18,550,437 $ - $ 18,550,437
14
NOTE 4 – EQUITY
2020
On January 28, 2020, we completed the sale of 3,448,278 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $1.45 per share in a registered direct offering. The ~~negative cash flow~~aggregate gross proceeds for the sale of the shares was ~~met by cash reserves.~~$5,000,003 and we received net proceeds of $4,517,102 after deducting offering costs of $482,901.
On February 13, 2020, we completed the sale of 3,324,676 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $3.08 per share in a registered direct offering. The ~~amount~~aggregate gross proceeds for the sale of the shares was $10,240,002 and we received net proceeds of $9,612,561 after deducting offering costs of $627,441.
On March 2, 2020, we completed the sale of 470,000 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $9.00 per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares was $4,230,000 and we received net proceeds of $3,882,420 after deducting offering costs of $347,580.
On March 5, 2020 we received $50,000 from the exercise of 25,000 unregistered warrants at an exercise price of $2.00 per share and issued 25,000 shares of our operating deficit could decrease or increase significantly depending on strategic and other operating decisions, thereby affecting our need for additional capital. We expect our operating losses will continue untilcommon stock.
During the three months ended March 31, 2020, we are able to generate revenue. Until our operations become profitable, we will continue to rely on proceeds received from external funding. We expect additional investment capital may come from (i) additional private placementsissued an aggregate of 2,133,333 shares of our common stock ~~with existing~~in conversion of 2,560,000 shares of our Series A Preferred Stock at a conversion price calculated by multiplying the number of preferred shares being converted by $100 and ~~new investors and (ii)~~dividing the ~~private placement~~result by $1.20.
During the three months ended March 31, 2020, we issued an aggregate of ~~other securities with investors similar~~694,492 shares of our common stock in relation to ~~those that have provided funding in~~ the ~~past.~~cashless exercise of 759,445 previously issued unregistered warrants.
During the three months ended March 31, 2020. we issued 12,363 shares of our common stock valued at $31,193 to 2 companies for investment relations services rendered.

~~Our continuation as a going concern is dependent on~~During the three months ended June 30, 2020, we received $220,000 from the exercise of 110,000 unregistered warrants at an exercise price of $2.00 per share and issued an aggregate of 110,000 shares of our ~~ability~~common stock to generate sufficient income and cash flow to meet our obligations on a timely basis and to obtain additional financing as may be required. The Company is actively seeking options to obtain additional capital and financing.four individuals.

~~Note 4 – Equity~~During the three months ended June 30, 2020, we received $643,465 from the exercise of 420,289 registered options by10 employees and two Members of our Board of Directors and issued an aggregate of 420,289 shares of our common stock.
During the three months ended June 30, 2020, we issued 9,689 shares of our commons stock valued at $86,050 to 3 companies for investment relations services rendered.

2019
InOn January 30, 2019, we entered into a securities purchase agreement with accredited investors ~~whereby the~~pursuant to which such investors purchased from ~~the Company~~an aggregate of 30,000 shares of Series A Convertible Preferred Stock of the Company for aan aggregate purchase price of $3,000,000. The purchase price was paid by the investors with $1.0 million in cash and the conversion of a $2.0 million promissory note ~~owed by~~of the Company issued to the investors. The investors may not convert the Series A Preferred Stock to the extent that such conversion would result in beneficial ownership by the investors and their affiliates of more than 4.99% of the issued and outstanding ~~Common Stock~~common stock of the Company. There is no mandatory redemption period required of the investors. Series A Convertible Preferred Stock is convertible to common stock at a conversion price calculated by multiplying the number of preferred shares being converted by $100 and dividing the result by $1.20.

InOn February 4, 2019, we completed the sale of an aggregate of 3,925,716 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $1.40 per share in a registered direct offering. The aggregate gross proceeds for the sale of the ~~Common Shares~~shares of common stock was $5,496,002 and we received net proceeds of $4,903,238 after offering costs of $592,764.

InOn March 7, 2019, we issued an aggregate of 166,667 shares of our common stock in relation to ~~an individual who converted~~ 2,000 shares of our Series A Preferred Stock being converted to common stock at a conversion price calculated by multiplying the number of preferred shares being converted by $100 and dividing the result by $1.20.

In June 2019, we issued 100,000 shares of our common stock to a company valued at $80,400 pursuant to a professional services agreement.
In September 2019, we issued 200,000 shares of our common stock to an individual who converted 2,400 shares of our Series A Preferred Stock to common stock at a conversion price calculated by multiplying the number of preferred shares being converted by $100 and dividing the result by $1.20.
~~In September 2019, we issued a total of 21,156 shares of our common stock to two companies with an aggregate value of $22,157 pursuant to professional services agreements.~~
~~2018~~
~~In March 2018, the Company issued 9,225 shares of our common stock valued at $25,000 to a company for services rendered.~~
~~In April 2018, the Company issued 13,368 shares of our common stock valued at $25,000 to a company for services rendered.~~
~~In June 2018, the Company issued 8,250 shares of our common stock valued at $25,000 to a company for services rendered.~~
~~On September 27, 2018 we issued 6,269 shares of our common stock valued at $15,000 in consideration of legal services performed by our attorneys.~~
~~On September 27, 2018, we issued 4,000 shares of our common stock valued at $10,520 to a limited liability company in consideration of services performed by the investor.~~
On September 27, 2018 and September 29, 2018, we issued 34,000 shares and 272,727, respectively, of our common stock with an aggregate value of $89,420 to a limited liability company. The 34,000 shares were issued in consideration of consulting services performed by the company. The 272,727 shares were issued pursuant to the exercise of a warrant in consideration of the payment of the exercise price of $30,000 by the company.
~~Note 5 – Notes Payable~~
On August 3, 2018, we entered into a Note Purchase Agreement with an existing shareholder of the Company and prior investor in the Company’s convertible debt securities. Pursuant to the agreement, the Company issued to the shareholder a Promissory Note, dated August 3, 2018, in the principal amount of $2,000,000 (the “Note”) in exchange for a loan to the Company of equal principal amount.
On January 30, 2019, we entered into a securities purchase agreement with investors, whereby the investors purchased from the Company 30,000 shares of Series A Convertible Preferred Stock of the Company for a purchase price of $3,000,000. The purchase price was paid by the investors with $1.0 million in cash and the conversion of a $2.0 million note owed by the Company to the investors. Upon conversion we recognized $78,241 as interest expense for the unamortized debt discount. For the nine months ended September 30, 2019 we included $106,409 in interest expense of which $15,000 was for interest paid and $91,427 was for accretion of note discount.

~~Note 6~~NOTE 5 – ~~Stock-based Compensation~~STOCK-BASED COMPENSATION

For the three and nine months ended September 30, 2019 we recognized $275,955 and $570,632, respectively as stock-based compensation. Of which $253,798 and $22,157, and $468,076 and $102,556, were as a result of granted option activity and common stock issuances, respectively, as described below and in Note 4 Equity above.
For the three and nine months ended September 30, 2018 we recognized $495,385 and $570,385, respectively as stock-based compensation. Of which $380,445 and $114,940 and $380,445 and $189,940 was the result of option and warrant activity, respectively, as described below and in Note 4 Equity above.
Stock Incentive Plans

The Co-Diagnostics, Inc. 2015 Long Term Incentive Plan reserves an aggregate of 6,000,000 ~~shares.~~shares of common stock issuable upon the grant of awards under the plan. The number of unissued ~~stock options~~awards authorized under the plan at ~~September~~June 30, ~~2019~~2020 was ~~3,978,183.~~3,828,183.

10 15
Stock Options

~~The Company estimates the fair value of incentive options on the date of grant as determined using~~We use a Black-Scholes ~~pricing model. The Company amortizes the fair~~model to value ~~of issued warrants using a vesting schedule based on the terms and conditions of each option. The Black-Scholes valuation model~~granted stock options which requires various judgmental assumptions including the estimated volatility, risk-free interest rate and expected ~~warrant~~option term. In determining the expected volatility our computation is based on the stock prices of ~~three~~3 comparable companies and is based on a combination of historical and market-based implied volatility. The risk-free interest rate iswas based on the yield curve of a zero-coupon U.S. Treasury bond on the date the option was ~~issued~~granted with a maturity equal to the expected term of the option. The ~~company applies a forfeiture rate discount in determining~~fair values for the ~~final valuation.~~options granted were estimated at the date of grant using the Black Scholes option-pricing model with the following weighted average assumptions:

~~For the three~~
Six months ended June 30,
2020 2019
Risk-free interest rate 1.05 % 1.56 %
Expected life (years) 7.3 10.0
Expected volatility 62.82 % 63.65 %
Expected dividend yield None None
Stock price $ 8.14 $ 1.07
We recognized $301,568 and ~~nine months ended September 30, 2019 we recognized $253,798 and $468,076~~$703,198 of stock-based compensation expense, related to stock options recorded in our general and administrative department of which (i) $19,483 and $19,483 was for 25,000 options granted to 1 independent member of the board of directors, (ii) $0 and $38,688 was for an aggregate of 75,000 options granted to 3 independent members of the board of directors, (iii) $146,520 and $146,520 was for vested portion of 790,000 options granted to 13 employees, and (iii) $87,795 and $263,385 was for options vesting which were granted prior to January 1, 2019, respectively.
~~Included in stock-based compensation~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2020 respectively, which is included in administrative and general expenses.
We recognized $126,483 and $214,278 of stock-based compensation expense, related to stock options for the ~~Company recognized expense of $380,445 recorded~~three and six months ended June 30, 2019, respectively, which is included in ~~our~~administrative and general ~~and administrative department for 850,000 options granted to nine employees.~~expenses.

The following table summarizes option activity during the ~~nine months and~~ year ended ~~September 30,~~December 31, 2019 and ~~December 31, 2018,~~the six months ended June 30, 2020, respectively.

Options
Outstanding Weighted
Average
Exercise
Price Weighted
Average
Fair
Value Weighted
Average
Remaining Contractual Life (years)
Outstanding at January 1, 2018 322,707 $ 1.29 $ 0.70 7.05
Options granted 850,000 2.63 1.24 9.98
Expired — — — —
Forfeited options — — — —
Exercised — — — —
Outstanding at December 31, 2018 1,172,707 $     2.23 $     1.09 8.72

Options granted 890,000 1.07 0.51 9.92
Expired — — — —
Forfeited options 40,890 3.85 1.59 8.04
Exercised — — — —

Outstanding at September 30, 2019 2,021,817 $ 1.69 $ 0.83 8.98
Unvested at September 30, 2019

810,000
$
1.64
$
0.77
9.60
Number of Options Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years)
Outstanding at January 1, 2019 1,172,707 $ 1.85 $ 1.09 8.72
Granted 890,000 1.07 0.52 9.66
Expired - - - -
Forfeited/Cancelled (40,890 ) 3.85 1.59 8.04
Exercised - - - -
Outstanding at December 31, 2019 2,021,817 $ 1.69 $ 0.83 8.73
Granted 150,000 8.14 4.70 7.30
Expired - - - -
Forfeited/Cancelled - - - -
Exercised (420,289 ) 1.53 0.79 7.62
Outstanding at June 30, 2020 1,751,528 $ 2.28 $ 1.21 8.50

The intrinsic value of options outstanding at June 30, 2020 and 2019 was $15,462,981 and $72,093, respectively. There were 843,333 and 566,667 of unvested option included the table above as of June 30, 2020 and 2019, respectively. At June 30, 2020 there were 843,333 unvested options.
Warrants

The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant. The Black-Scholes valuation model requires various judgmental assumptions including the estimated volatility, risk-free interest rate and expected warrant term. In determining the expected volatility, our computation is based on the stock prices of three comparable companies and on a combination of historical and market-based implied volatility. The risk-free interest rate is based on the yield curve of a zero-coupon U.S. Treasury bond on the date the warrant was issued with a maturity equal to the expected term of the warrant.
There were 470,000 warrants valued at $379,487 issued in the nine months ended September 30, 2019 for professional services rendered to the company. The Company calculated the value of the warrants using a Black-Scholes pricing model with the following assumptions: (i) risk free interest rate 2.34%, (ii) expected life (in years) of 5; (iii) expected volatility of 50.97%; (iv) expected dividend yield of 0.00%; and (v) stock trading price of $0.982.
16

~~There were no warrants issued in the three and nine months ended September 30, 2018.~~

The following table summarizes warrant activity during the ~~nine months and~~ year ended ~~September 30,~~December 31, 2019 and ~~December 31, 2018,~~the six months ended June 30, 2020, respectively.

Warrants
Outstanding Weighted
Average
Exercise
Price Weighted
Average
Fair Value Weighted
Average
Remaining Contractual
Life (years)
Outstanding at January 1, 2018 706,262 3.27 1.48 4.22
Warrants issued 50,000 2.00 1.22 5.00
Expired — — — —
Forfeited warrants — — — —
Exercised 272,727 0.64 0.54 3.64
Outstanding at December 31, 2018 483,535 $     4.92 $      1.99 3.29

Warrants issued 470,000 0.48 0.08 4.59
Expired — — — —
Forfeited warrants — — — —
Exercised — — — —

Outstanding at September 30, 2019 953,535 $ 2.73 $ 1.05 3.55
Number of Warrants Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years)
Outstanding at January 1, 2019 483,535 $ 4.92 $ 1.99 3.29
Granted 500,000 1.53 1.46 5.00
Expired - - - -
Forfeited/Cancelled - - - -
Exercised - - - -
Outstanding at December 31, 2019 983,535 $ 1.44 $ 1.03 3.34
Granted 20,000 16.49 15.19 5.00
Expired - - - -
Forfeited/Cancelled - - - -
Exercised (894,445 ) 1.37 1.05 2.80
Outstanding at June 30, 2020 109,090 $ 2.06 $ 1.17 3.62

The ~~following table summarizes information about stock~~intrinsic value of options and warrants ~~outstanding at September~~exercised in the six months ended June 30, ~~2019.~~
Outstanding Exercisable
Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual
Life (years) Weighted Average
Exercise
Price Weighted Average
Exercise
Price
$ 0.01-1.10 1,511,372 7.95 $ 0.73 984,705 $ 0.53
2.00-3.85 1,055,445 8.12 2.54 772,112 2.51
5.10-7.20 408,535 2.34 5.46 408,535 5.46
$ 0.01-7.20 2,975,352 7.24 $ 2.02 2,165,352 $ 2.16
2020 was $16,083,097. Total unrecognized stock-based compensation was ~~$581,167~~$468,295 at ~~September~~June 30, ~~2019~~2020 for options granted. The Company expects to recognize the aggregate amount of this compensation expense over the next years in accordance with contractual provisions and vesting as follows:

Year Amount
2019 $ 121,607
2020 369,379
2021 90,181
Total $ 581,167
Year Ending December 31,
2020 $ 198,148
2021 234,149
2022 35,998
Total $ 468,295

~~Note 7~~NOTE 6 – ~~Related Party Transactions~~RELATED PARTY TRANSACTIONS

The Company acquired the exclusive rights to the CoPrimer technology pursuant to aan exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between usthe Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, one of our current executive officers, prior to our acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provides in part that all accrued royalties under the License cease as of January 1, 2017, and we began in January 2017 to pay to Dr. Satterfield $700,000 of accrued royalties at the rate of $10,000 per month. At ~~September~~June 30, ~~2019,~~2020, the aggregate balance of this related party liability was ~~$290,000.~~$200,000.

~~Note 8~~NOTE 7 – ~~Lease Obligations~~LEASE OBLIGATIONS

Our offices are located at 2401 S. Foothill Dr., Suite D, Salt Lake City, Utah 84109-1479. ~~On June 18, 2018,~~In February 2020, the Company entered into a 4-year lease agreement for its office space and in March 2020, the Company entered into an addendum with our landlord for additional space. The new aggregate space consists of approximately ~~10,273~~13,687 square feet ~~and is leased under a multi-year contract~~ at a monthly rate of ~~$14,086 per month expiring on January 31, 2020.~~$28,825 and expires in February 2024. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020 the Company expensed ~~$42,259~~$86,969 and ~~$132,879,~~$138,787, respectively, for rent. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2018,~~2019, the Company expensed ~~$46,540~~$45,040 and ~~$122,165,~~$90,621, respectively, for rent. The Company’s ~~remaining~~ongoing lease ~~rent~~ obligation as of ~~September~~June 30, ~~2019~~2020 is as follows:

Year Amount
2019 $ 42,258
2020 14,086
Total $ 56,344
Year Ending December 31,
2020 (remainder) $ 172,950
2021 345,900
2022 345,900
2023 345,900
2024 57,653
Total lease payments $ 1,268,303

~~Note 9~~NOTE 8 – ~~Subsequent Events~~SUBSEQUENT EVENTS

~~On October 22, 2019,~~In August, 2020, we ~~issued 3,000 shares~~discovered that a freezer that held manufactured tests had failed and that approximately $1,200,000 of ~~our common stock valued at $3,180 to an entity that provides services for the Company pursuant to a~~finished goods inventory had thawed and was no longer saleable and will be written ~~contract.~~off.

17
~~The Company evaluated subsequent events pursuant to ASC Topic 855 and has determined that there are no additional events that need to be reported.~~
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report and the documents incorporated by reference herein, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors and the documents incorporated by reference herein, which may affect our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations, and financial needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Quarterly Report, and in particular, the risks discussed below and under the heading “Risk Factors” in other documents we file with the SEC. The following discussion should be read in conjunction with the Annual Report on Form 10-K for the fiscal ~~years~~year ended December 31, ~~2018 and 2017, notes incorporated by reference therein and other reports~~2019 filed with the ~~SEC. We undertake no obligation to revise or publicly release~~SEC on March 30, 2020 and the ~~results of any revision to these forward-looking~~audited financial statements ~~except as required by law. In light of these risks, uncertainties~~ and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statement.notes included therein.

~~Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:~~
18

● ~~our ability complete capital raising transactions to fund continuing operations;~~
● ~~our ability to develop and commercialize new and improved products and services;~~
● ~~market acceptance of any products that may be approved for commercialization;~~
● ~~our ability to protect our intellectual property rights;~~
● ~~the impact of any infringement actions or other litigation brought against us;~~
● ~~competition from other providers and products;~~
● ~~the results of clinical trials and the regulatory approval process;~~
● ~~the results of clinical trials and the regulatory approval process;~~
● ~~changes in government regulation;~~
● ~~and other factors relating to our industry, our operations and results of operations.~~

You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Quarterly Report. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Quarterly Report to conform our statements to actual results or changed expectations.
You are advised, however, to consult any further disclosures we make on related subjects in our periodic and current reports filed with the SEC. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider this list to be a complete set of all potential risks or uncertainties.
Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:
● the results of clinical trials and the regulatory approval process;
● market acceptance of any products that may be approved for commercialization;
● our ability to protect our intellectual property rights;
● the impact of any infringement actions or other litigation brought against us;
● competition from other providers and products;
● our ability to develop and commercialize new and improved products and services;
● changes in government regulation; and
● other factors (including the risks contained in the section entitled “Risk Factors” in other documents we file with the SEC) relating to our industry, our operations and results of operations.
Critical Accounting Policies

The preparation of financial statements in conformity with U.S. GAAP requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our assumptions and estimates, including those related to recognition of revenue, valuation of investments, valuation of inventory, ~~valuation of intangible assets,~~ measurement of stock-based compensation expense and litigation. We base our estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

As an emerging growth company, we have elected to opt-in to the extended transition period for new or revised accounting standards. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates.

Executive Overview

The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition. This discussion should be read in conjunction with the accompanying unaudited financial statements and notes thereto included elsewhere in this report. The information contained in this discussion is subject to a number of risks and uncertainties. We urge you to review carefully the section of this report entitled ““Cautionary Note Regarding Forward-Looking ~~Statements~~”Statements” for a ~~more complete discussion~~summary of the risks and uncertainties associated with an investment in our securities.
19

Overview

Co-Diagnostics, Inc. ~~(“we,” “our,”~~, a Utah corporation (the “Company” or ~~“Company”~~“CDI”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. We ~~are a molecular diagnostics company that has~~have developed and ~~intends to~~ manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of our ~~test products~~tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx ~~device”~~Device”).

Our diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. ~~Our newest~~CDI’s technical advance involves a novel approach to ~~PCR~~Polymerase Chain Reaction (“PCR”) test design of primer and probe structure (“CoPrimers”) that eliminates one of the key vexing issues of PCR amplification, ~~occurring especially in multiplexed transactions, which is~~ the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely ~~interfering~~interferes with identification of the target DNA.

~~Our~~We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. Because we own our platform, we ~~are~~believe we will be able to accomplish this faster and more economically, allowing for ~~wider~~significant margins while still positioning usthe Company to be a low-cost provider of molecular diagnostics and screening services.

In addition, continued development has demonstrated the unique properties of our CoPrimer technology that make ~~them~~it ideally suited to a variety of applications where specificity is key to optimal results, including multiplexing several targets, ~~simultaneously,~~ enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next gen sequencing.
Our scientists ~~were the first to understand~~use the complex mathematics of ~~DNA~~DNA/RNA test design, to ~~“engineer” primers~~engineer and ~~probes for DNA tests~~optimize a DNA/RNA test and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. Dr. Satterfield, our Chief Technology Officer, developed the Company’s intellectual property consisting of the predictive mathematical algorithms and proprietary reagents used in the testing process, which together represent a major advance in ~~Polymerase Chain Reaction (“PCR”)~~PCR testing systems. ~~Our~~CDI technologies are now protected by seven granted or pending US orand foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which enables the sale of diagnostic tests at a lower price than competitors, while enabling us to maintain profit margins.

We may either sell or lease the MDx Device to ~~existing~~labs and diagnostic centers, through sale or lease agreements, and sell the reagents that comprise our proprietary ~~test products~~tests to those laboratories and testing facilities.

We designed our tests by identifying the optimal locations on the target gene for amplification and paired the location with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and testing. In other words, the data resulting from our tests verify that we succeeded in designing what we intended at the outset. Verification is a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our lab or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs.
Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval in the European Community and in India to sell PCR diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus. In the United States, CDI has obtained Emergency Use Authorization (“EUA”) for its COVID-19 test from the FDA and sells that test to qualified labs. In addition, our LogixSmart COVID-19 test has been approved for sale in Australia and Mexico by the regulatory bodies in those countries.
In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describe any type of genetic trait, which creates a number of significant applications. We, in conjunction with our customers, are active in designing and licensing tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in spraying mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses.
20
Recent Developments
On January 23, 2020, we announced the completion of the principle design work for a PCR screening test for new coronavirus, COVID-19, intended to address potential need for detection of the virus. An outbreak of respiratory illness caused by the pneumonia-like COVID-19 has spread rapidly throughout the world since first being discovered in the Chinese city of Wuhan on December 31, 2019. China confirmed human-to-human transmission of the virus and the United States announced the first infection in this country, detected in a traveler returning from Wuhan. Our COVID-19 test features the Company’s patented CoPrimer™ technology, and was designed using our proprietary software system, following the guidelines published by the World Health Organization (WHO) and Centers for Disease Control (CDC).
On February 20, 2020, we announced that our Logix Smart™ COVID-19 Test technical file had been submitted for registration with the European Union, and that it was expected to be available late February as an in vitro diagnostic (“IVD”) for markets that accept a CE marking as valid regulatory approval. Subsequently, on February 24, 2020, we announced that our test obtained regulatory clearance to be sold as an IVD for the diagnosis of COVID-19 in markets that accept CE-marking as valid regulatory approval, and became available for purchase from the Company’s Utah-based ISO-13485:2016 certified facility. The Declaration of Conformity for the Logix Smart COVID-19 test confirms that it meets the Essential Requirements of the European Community’s In-Vitro Diagnostic Medical Device Directive (IVDD 98/79/EC), permitting export and sales of the product as an IVD to commence immediately in the European Community. We shipped samples of the Research Use Only version of our test to distributors in various countries, which allowed future customers to confirm the quality and sensitivity of the product, and for us to accelerate the sales efforts of the COVID-19 test.
We commenced sales of the COVID-19 tests in February and March of 2020 to international customers and sold the tests in numerous countries around the world through an expanding distributor network.
On April 6, 2020, we announced that we had received an Emergency Use Authorization from the FDA allowing us to commence sales of our Logix Smart COVID-19 test to laboratories certified by the Center for Medicare and Medicaid Services under the Clinical Laboratories Improvements Act (“CLIA”) to accept human samples for diagnostics testing throughout the United States and we have been actively marketing to such CLIA labs since that time.
Infectious Disease Product Offering
Using its proprietary test design system and proprietary reagents, CDI designs and sells PCR diagnostic tests for diseases and pathogens such as COVID-19, tuberculosis, hepatitis B and C, malaria, dengue, human papilloma virus, chikungunya, and zika virus, all of which tests have been designed and verified in CDI’s laboratory. Our tuberculosis test and zika test received a CE Mark in 2018, and a triplex test for zika, dengue and chikungunya received a CE Mark in 2019, qualifying the tests to be sold throughout the European community and in most countries in central and South America. In December, 2019, our Indian joint venture received a license to manufacture and sell tuberculosis, hepatitis B, hepatitis C, human papilloma virus 16/18 and malaria tests in India from the Central Drugs Standard Control Organization (“CDSCO”). In February 2020, we received a CE Mark for our Logix Smart COVID-19 test and in April 2020, our COVID-19 test was approved for manufacture and sale in India by the CDSCO and in Mexico by the INDRE, Mexico’s equivalent to the United States Center for Disease Control. In August 2020, we received approval from the Australian Department of Health Therapeutic Goods Division to sell our COVID-19 in Australia.
As explained above, the development of our Logix Smart COVID-19 test was designed, developed, submitted for regulatory approved and ready to be used both as a Research Use Only (“RUO”) and as an IVD in countries that accept a CE Mark as approval for use of the test in a period of just over thirty days. This is a real-world example of how in an evolving epidemic that the CDI technology can be used to get diagnostics tools in the hands of medical professionals without delay. It can be similarly used to design a test for mutations of the virus should they occur.
~~Agreement with Synbiotics~~Caribbean and Central and South America

~~The~~Our initial sales were to entities located in South and Central America.
21
In some of those countries, there are limited regulatory hurdles and sales we started offering our tests immediately. We have applied for registration of our tests in those countries that require registration and our distributors in those countries have provided us with in country assistance in completing such registrations.
We first offered our zika test in this region because of the demand for such test, followed quickly by tests for tuberculosis, our triplex test for zika, chikungunya, and dengue, hepatitis B and C, and dengue. Sales of those tests have not been material, but with the granting of a CE mark for our Logix Smart COVID-19, we began significant sales in this region. Products are manufactured for sale upon receipt of purchase orders from distributors, labs and hospitals.
India
In January, 2017, the Company ~~has~~ entered into ~~a joint venture~~an agreement to manufacture diagnostics tests for seven infectious diseases with ~~Synbiotics Limited,~~ a pharmaceutical manufacturing company in ~~India. The Company~~India and ~~Synbiotics are equal partners in the~~formed an Indian joint ~~venture.~~venture organized as CoSara Diagnostics, Pvt. The agreement ~~provides~~provided for the ~~constructions~~construction of a manufacturing plant toand the manufacture of the tests named above and the joint sales and marketing of those tests in India. ~~The Company will~~We have received a license ~~its technology to the joint venture on a royalty-free basis. The profits from the partnership shall be divided as follows:~~
Profit Level
Co-Diagnostics, Inc.
Share Synbiotics Share

Up to $1,000,000 50 % 50 %
$1,000,000-$2,000,000 60 % 40 %
$2,000,000-$3,000,000 70 % 30 %
Above $3,000,000 80 % 20 %
~~Synbiotics will be reimbursed by the joint venture for some expenses, such as approximately $96,000 in rent~~ for the ~~manufacturing~~ plant in Rinoli, India to manufacture approved tests and ~~office space and the services of some of Synbiotics’ employees. If the joint venture needs additional funding,~~ it will be ~~achieved~~used for testing and manufacturing for the Indian market.
As mentioned above, the CDSCO has given us the approval for manufacture and sale of the five tests referred above and the Company has begun manufacture and sale of those tests. Sales of those tests has not been material to date. The Company has commenced a reagent rental program in India with a thermocycler purchased from a third-party vendor and which we refer to as our MDx Device. We have placed twenty-one of our MDx Devices with labs in India. Each of the reagent rental placements requires the purchase of a minimum of 250 tests per month. India is the country with the highest burden of tuberculosis. World Health Organization (WHO) tuberculosis statistics for India for 2015 give an estimated incidence figure of 2.2 million cases of tuberculosis for India out of a global incidence of 9.6 million. The tuberculosis incidence for India is the number of new cases of active tuberculosis disease in India during a certain time period (usually a year). We believe that we will be able to sell our tuberculosis test in India through ~~loans obtained by the~~our sales distribution network that we are building currently.
On March 19, 2020, we announced that CoSara Diagnostics, Pvt., our Indian joint venture ~~or if loans~~(“CoSara”), received authorization to begin manufacture and sale of COVID-19 tests in India. Those tests in India are branded as SaraGene COVID-19 tests and are sold exclusively by CoSara. Because any commercial activity in India was severely restricted until May 2020, CoSara was not ~~available on commercially reasonable terms, from capital contributions. There is no term~~able to commence the manufacturing and sale of the SaraGene COVID-19 tests until late in the second quarter, but sales efforts still resulted in sales significant enough to make CoSara profitable for the quarter ending June 30, 2020.
Although the efforts of CoSara are currently concentrated in providing the SaraGene COVID-19 test to the ~~joint venture agreement but it can be dissolved by mutual agreement or by one party upon a material breach by the other party. The manufacturing plant is completed and is ready for production and~~Indian market, we are ~~waiting for final approval by the Indian regulatory body responsible for sales of such products (“CDSCO”). We have submitted or will~~preparing to submit technical files ~~describing seven different diagnostic tests~~ to the CDSCO requesting approval tests for ~~those~~the human immunodeficiency virus (HIV) and dengue as well as a blood bank panel before the end of the third quarter of 2020 to increase the number of tests to be ~~manufactured~~sold in that market.
Europe
Molecular diagnostics, such as our ~~plant~~tests, are governed in Europe by the framework for in vitro diagnostics (IVDs), which encompasses diagnostic products such as reagents, instruments and systems intended for use in diagnosis of disease. The regulatory system for IVDs is built largely on a self-certification procedure, placing heavy responsibility on manufacturers. Non self-certified products are subject to the same standards as self-certified products but are subject to audit and review by a notified body prior to receiving approval to be CE-marked. A CE-marking is a manufacturer’s declaration that a product meets the requirements of the applicable European Commission directive. Examples of current obligations include having in place a qualitative manufacturing process, user instructions that are clear and fit for purpose, ensuring that the ‘physical’ features of devices and diagnostics do not pose any danger. If a product fulfils these and other related control requirements, it may be CE-marked as an indication that the product is compliant with EU legislation and sold in the ~~Indian market. The technical files for three of the tests have been reviewed by the CDSCO and we are waiting for final approval to begin manufacturing and selling the tests.~~European Union. We have received ~~test licenses~~CE Marks for ~~various diseases allowing us~~four of our tests including COVID-19, tuberculosis, Zika, and our zika, dengue, chikungunya triplex tests.
We have received ISO 13485 and ISO 9001 certifications relating to ~~sell test products for research.~~the design and manufacture of our medical device products. The ~~joint venture is currently marketing~~ISO certification indicates that we meet the standards required to self-certify certain of our products ~~in the Indian market~~ and ~~has commenced sales of our probes and primers to various laboratories and other users to be used as Research Use Only tests in their facilities, which are the beginning of~~affix a CE-marking for sales of our products in ~~India.~~countries accepting the CE marking (not in the United States) with only minimal further governmental approvals and registrations in most countries.
22
United States
The U.S. Food and Drug Administration (FDA) has granted permission for us to export all of our IVD our products. The FDA’s permission to export was granted under Section 801(e) of the Federal Food, Drug, and Cosmetic Act, as amended (the “FDC Act”). Section 801(e) of the FDA Act covers certain medical devices that have not yet received an approved Premarket Approval in the United States by the FDA, such as our products. We have not commenced any Premarket Approval steps with the FDA. Section 801(e) of the FDA Act applies to medical devices that are acceptable to the importing country and that are manufactured under the FDA’s Good Manufacturing Practices. We have received Emergency Use Authorization (EUA) for our COVID-19 test, which allows sales to qualified labs in the United States.
Under our EUA we are actively marketing our LogixSmart COVID-19 test to CLIA certified laboratories in the United States and the CLIA labs are able to qualify our LogixSmart test as a Laboratory Developed Test (LDT), a diagnostic test that has been validated for use in the CLIA lab. These tests may be used by the lab only in that laboratory. CLIA laboratories develop the performance characteristics, perform the analytical validation for their LDT’s and obtain licenses to offer them as diagnostic services. The FDA has publicly announced its intention to regulate certain LDTs in a phased-in approach, but draft guidance that was published a couple of years ago was withdrawn at the end of the Obama administration and replaced by an informal non-enforceable discussion paper reflecting some of the feedback that it received on LDT regulation. We are currently marketing to CLIA laboratories throughout the US.
Market Opportunity
The market opportunity for our tests changed radically with the emergence of the COVID-19 pandemic. Because we were able to respond rapidly and produce a quality product, we have been able to build a distribution network that extends to more than 80 countries with over 50 active distributors, most of which have been the sales network that has allowed us to export products throughout the world. We believe that after the pandemic is brought under control, the network of distributors that we have built in these extra-ordinary times will serve us well in sales of other diagnostic tests.
The molecular diagnostics market is a fast-growing portion of the in vitro (test tube-based, controlled environment) diagnostics market. Using estimates of the incidence of disease by the Centers for Disease Control (CDC), the World Health Organization (WHO) and other international health agencies and sources, the Company estimates that the global annual demand for diagnostic tests are:
Tuberculosis 10,400,000
Multi-drug resistant Tuberculosis 580,000
Zika 324,000,000
Hepatitis B 240,000,000
Hepatitis C 130,000,000
HIV 36,700,000
Malaria 214,000,000
Sexually Transmitted Illnesses 357,000,000
Human papilloma virus 291,000,000
Dengue 390,000,000
Total Annual Tests 1,993,680,000
There are several advantages of molecular tests, such as the ones we market and sell, over other forms of diagnostic testing. These advantages include higher specificity sensitivities, the ability to perform multiplex tests and the ability to test for drug resistance or individual genes.
23
Mosquito Vector Control Services
In response to market demand, we introduced our first diagnostics tests to be used exclusively to test for mosquito borne pathogens in June 2019. Municipalities in the US and many other countries in the world are concerned about the diseases carried by mosquitos and which infect the human population. To prevent outbreaks of potentially harmful viruses, such as zika or west nile, from infecting the public the municipalities conduct spraying operations to eliminate the mosquito populations carrying the diseases. Because it is too expensive and potentially harmful to the environment to spray all mosquito breeding areas, the problem is to identify which particular area has mosquitos that are carrying the harmful viruses. To know where the host mosquitos with the harmful viruses are located, traps are set, mosquitos collected and then tested to find the areas that most needed spraying. There are over three thousand mosquito abatement districts throughout the United States and almost all of them conduct testing to help make the spraying more effective.
Our first vector related test was a triplex test that tests for west nile, western equine and St. Louis encephalitis. We began shipping the tests in June 2019. We added a second test that tests mosquitos for zika, chikungunya and dengue in a triplex test. Finally, in November 2019, we completed a test for west nile, eastern equine and St. Louis encephalitis, specifically for use in the eastern United States. As a result, mosquito abatement districts can test for three target viruses in one test as compared to needing to perform three different tests using other market available PCR tests, which saves our customers money. Additionally, the districts are more effective because they can get test results in a matter of hours using our product instead of weeks when they have to wait for a central lab to process the mosquito tests.
We have sold our Vector Smart test products and/or related lab equipment to testing districts in in different sections of the country and are marketing our products through trade shows, electronic and regular mail solicitations and have hired additional sales personnel in the eastern US to more economically and efficiently market to the east coast areas.
Competitive Advantages of Co-Diagnostics
We believe that we have the following competitive advantages:
● Affordability: Lower-cost test kits and low-cost MDx Device.
● Flexibility: Our tests have been designed to run on many vendors’ DNA diagnostic testing machines. These tests are particularly well suited to the new generation of “lab-on-a-chip” and “point-of-care” (“LOC” and “POC”), highly portable analysis machinery for field, clinic and office applications.
● Speed: We believe our rapid assay design system software provides shorter time to product release. This has been demonstrated with the conception, design, product manufacture, clinical verification and submission for a CE Mark for our Logix Smart coronavirus disease (COVID-19) test being approximately 30 days.
● Accuracy: We believe our tests are more sensitive and specific than competitors’ and can detect more strains of viruses.
● Exclusivity: We own all patents and all intellectual property used in preparation of our tests.
24
● Personalized Medicine: We project that rising health care costs in developed and developing nations will increasingly require that health care systems be patient specific to eliminate waste, misdiagnoses, and ineffectiveness. We believe a critical component will be accurate, more affordable DNA/RNA-based diagnostics, which we plan to offer.
● Low-cost Provider: We plan to keep our overhead low. Our platform technology obviates the need to pay patent royalties typically required of our competitors which use patented test platforms to design their tests.
● Worldwide Footprint: With a dynamic technology that encompasses markets worldwide, we anticipate that we can identify the best target markets, not only in highly burden developing countries (HBDC’s) but also in developed nations.
● Growth Industry Category: We believe that DNA/RNA testing is the fastest-growing segment of in-vitro diagnostic testing.
● Combination Product Offering: Our ultra-sensitive tests can be a well-designed match for a new generation of handheld and other small point-of-care (POC) devices now entering the market. Used together, these affordable tests and devices may revolutionize the molecular diagnostics industry in cost, speed of test results and simplification.
● Multi-plexing: Our existing multiplexed tests demonstrate that our CoPrimer designed tests are able to test for multiple targets in the same sample without the distortion caused by false negatives and false positives that generally occur in multiplexed tests.
Liquid Biopsy for Cancer Screening
The development of the liquid biopsy test will be expected to spur low cost testing in many developing countries. We believe that our liquid biopsy cancer screening may be ready for testing in the second quarter of 2021 if we have sufficient development resources to dedicate to the project. Medical applications of our SNP detection technology can determine the presence of cancer cells or cell-free genetic material in a liquid or tissue biopsy, and to determine the distinct type of cancer involved. A real-life example of this includes being able to identify specific mutation(s) in genes linked to breast cancer in order to determine a patient’s prognosis, initiate the most effective and affordable treatment and to determine whether chemotherapy is necessary. After diagnosis the relative cost of our technology would allow for frequent testing to measure the effectiveness of the treatment and thus could be a companion diagnostic for a range of treatments.
Our technology has for all practical purposes essentially eliminated, primer-dimers, which opens up some very unique applications for liquid biopsy for cancer detection. Our ability to multiplex the reaction in testing for several DNA targets allows technicians to detect multiple cancers as free-circulating DNA fragments or whole cells in a blood sample at the same time
Agricultural Applications
SNP detection is also used in the agricultural industry to identify variations in crop genomes to achieve improved seed viability and other desired characteristics, including drought resistance, disease resistance, pest resistance and higher yield.
In mid-2017, the Company was first approached by a large agribusiness to evaluate our ability to multiplex certain target genomes. The results of the development project have successfully demonstrated our ability to not only multiplex the target genomes, but targeted SNP’s as well. The project was undertaken in conjunction with the manufacturer of our CoPrimer tests. The results of the project encouraged the parent of our manufacturer to seek a world-wide licensing arrangement for our CoPrimers in the agricultural industry, which was completed in October 2018. Pursuant to the exclusive license for the agronomics industry, the licensee will pay us a royalty for all CoPrimers sold to the licensee’s customers. In January 2019, the licensee formally introduced the product at a large agricultural conference and has branded the product to sell as “BHQ CoPrimers”.
25
Additional Licensing and Assay Development
In addition, the unique properties of our CoPrimer technology make them ideally suited to a variety of applications where sensitivity is key to optimal results, including multiplexing several targets, enhanced SNP detection and enrichment for next generation sequencing. Our licensee for our agricultural testing requested an expansion of our license agreement to include test design services for their customers and potential customers, both in the infectious disease arena as well as for agricultural customers. The license was amended in July 2019 and we will derive a license fee from our licensee for its design services. If any of its customers desire to commercialize the tests designed, they will need to seek a commercial license directly from us. Because of these unique characteristics of CoPrimers, research companies and institutions have requested that we design diagnostics to locate and identify uncommon gene sequences and SNPs and create tests for the target sequences in a multiplexed reaction. This application of our technology is in its beginning stages, but we believe that the results from our initial research indicate a significant step forward in defining the capabilities of our technology, which we believe can be translated to revenue producing licensing arrangements.

Intellectual Property Protection

Because much of our future success and value depends on our proprietary technology, our patent and intellectual property strategy is of critical importance. ~~Four~~Five of our initial U.S. patents related to our technology have been granted by the U.S. Patent and Trademark Office ~~or PTO,~~(PTO), including the patent for our CoPrimer technology, which we consider our most important patent. One of our patents has been issued in Great ~~Britain.~~Britain, but is still pending in the United States. As of ~~September 30, 2019,~~July 31, 2020, we had ~~four~~two additional patents pending in the U.S. and foreign counterpart applications. Two of our issued patents expire in 2034, one in 2036 and one in 2038.

We have identified additional applications of the technology, which represent potential patents that further define specific applications of the processes that are covered by the original patents. We intend to continue building our intellectual property portfolio as development continues and resources are available.

We have copyrighted our development software that ~~can be~~is used by ~~any lab or developer~~us to develop diagnostic tests based on our technology. We have allowed one potential customer access to our development software and intend to sell customized reagents through that customer to labs serviced by that customer throughout the world. To date we have not sold any products to that customer.

16
Major Customers

~~We currently~~The Company had certain customers which are each responsible for generating 10% or more of the Company’s total revenue for the three and six months ended June 30, 2020. These three customers together accounted for approximately 58% and 55% of the Company’s total revenue for the three and six months ended June 30, 2020, respectively. These customers may not account for the same percentage of sales in future periods. If we were to sell nothing to those customers in the future, it would have ~~no major customers.~~a material adverse effect on our financial condition unless we were able to replace those customers with others.

Competition

The molecular diagnostics industry is extremely competitive. There are many firms that provide some or all of the products we provide and provide many diagnostic tests that we have yet to develop. Many of these competitors are larger than us and have significantly greater financial resources. Because we are not established, many of our competitors have a competitive advantage in the diagnostic testing industry because they also have other lines of business in the pharmaceutical industry from which they derive revenues and for which they are well known and respected in the medical profession. We will need to overcome the disadvantage of being a start up with no history of success and no significant respect offrom the medical and testing ~~professionals.~~professionals, although this is changing as we continue to market our LogixSmart COVID-19 tests in the United States to well-known and successful laboratories. In the diagnostic testing industry, we compete with such companies as BioMerieux, Siemens, Qiagen, and Cepheid and with such pharmaceutical companies as Abbott Laboratories, Becton Dickinson and Johnson and Johnson.

26
Many of these competitors already have an established customer base with industry standard technology, which we must overcome to be successful.

Competition is, and will likely continue to be, particularly intense in the market for COVID-19 diagnostic tests. Numerous companies in the United States and internationally have announced their intention to offer new products, services and technologies that could be used in substitution for our LogixSmart COVID-19 tests Many of those competitors are significantly larger, and have substantially greater financial, engineering and other resources, than our company. Existing and potential competitors in the market for COVID-19 diagnostic tests include developers of both serological and molecular tests.

We expect competition to continue to increase as other established and emerging companies enter the market, as customer requirements evolve, and as new products, services and technologies are introduced. The entrance of new competitors is being encouraged by governmental authorities, who are offering funding to support development of testing solutions for COVID-19. For example, on April 29, 2020, the U.S. National Institutes of Health announced it would be using a portion of its $1.5 billion in federal stimulus funding to fund a $500 million national challenge designed to help the agency identify the best candidates for an at-home or point-of-care test for COVID-19. Some of our existing or new competitors may have strong relationships with current and potential customers, including governmental authorities, and, as a result, may be able to respond more quickly to new or changing regulatory requirements, new or emerging technologies, and changes in customer requirements.
Employees

We currently employ 2137 full-time personnel at our executive offices and lab facilities in Salt Lake City, Utah, and two employees outside of Utah. We have engaged independent contractors in India to promote the use of our products and develop outlets for products and employ the services of independent sales representatives on an “as needed” basis.

Government Regulation

WeIn the United States, we will be regulated by the U.S. Federal Drug Administration (FDA) and our products must be approved by the FDA before we will be allowed to sell our tests in the United States. However, the FDA granted us an Emergency Use Authorization (EUA) to manufacture and sell our Logix Smart COVID-19 test to CLIA labs in the United States. Because our lab is ISO certified, we are allowed to apply for CE-Marking, which will allow us to sell any CE Marked test in most countries in Europe, South America and Asia. We currently have CE Marks issued for our Logix Smart COVID-19 test, tuberculosis test, our zika virus test, and a triplex test that tests for zika, dengue, and chikungunya simultaneously. In addition, our Logix Smart COVID-19 has received the license to manufacture and sell in India from India’s CDSCO and the National Epidemiology Institute in Mexico evaluated our Logix Smart COVID-19 test and approved it for sale in Mexico. We are in the process of registering for sale our Logix Smart COVID-19 test ~~products~~ in ~~various~~a number of major countries ~~in South and Central America and Africa.~~around the world.

Organizational History and Corporate Information

We were incorporated as Co-Diagnostics, Inc. in Utah on April 18, 2013. Our principal executive office is located at 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109. Our telephone number is (801) 438-1036. Our website address ishttp://codiagnostics.com. The ~~information included on~~contents of our website isare not ~~and shall not be interpreted to be, a part of~~incorporated by reference in this ~~quarterly report.~~Quarterly Report.

RESULTS OF OPERATIONS

Results of Operations for the ~~Nine~~Six Months ended ~~September~~June 30, ~~2019~~2020 and ~~2018~~2019

Net Sales

For the ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, we generated ~~$106,408~~$25,588,802 of net sales compared to net sales of ~~$29,088~~$64,974 in the ~~nine~~six months ended ~~September~~June 30, ~~2018.~~2019. The increase in sales of $25,523,828 was primarily due to sales of our LogixSmart COVID-19 test due to the current COVID-19 pandemic. Of the total sales, $1,782,312 was from the sale of third party manufactured equipment that we sourced and sold to customers to facilitate usage of our test. $49,800 of the revenue in 2019 ~~represents~~was the result of sales of equipment ~~sold~~and tests to two mosquito abatement districts ~~of $63,800~~ and the remainder was sales of ~~testing products of $42,608. The 2018 revenue represented a license fee for licensing~~ our ~~Zika tests and certain other Flaviviruses to a Canadian company for limited distribution. That license has since been terminated.~~test reagents.

Cost of Sales

For the ~~nine~~six months ended ~~September~~June 30, 2020, we recorded cost of sales of $6,457,045, of which $4,805,650 was the cost of test reagents sold and $1,651,395 was the cost of equipment sold. For the six months ended June 30, 2019, we recorded cost of sales of ~~$49,173 related to equipment sales and $10,453 related to sales of testing products. For~~$39,261 primarily for the ~~nine months ended September 30, 2018, we recorded no~~ cost of ~~sales.~~equipment included in the sales to mosquito abatement districts.
27
Operating Expenses

We incurred total operating expenses of ~~$4,317,125~~$5,505,429 for the ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 compared to total operating expenses of ~~$4,323,654~~$2,645,969 for the ~~nine~~six months ended ~~September~~June 30, ~~2018. Total~~2019. The increase in operation expenses ~~decreased by only $6,529 but~~was due to the ~~categories of expenditures changed materially. There was a decrease~~increase in general and administrative expenses of $371,989, which was offset by an increase of $351,129 in our sales and marketing expenses. Research and development expenses remained basically constant in that they increased by less than 1% or $5,197. Depreciation and amortization expense also increased $9,134business activities experienced as a result of the ~~purchase of additional equipment.~~sales increases due to the COVID-19 pandemic.

General and administrative expenses ~~decreased $371,989~~increased $2,202,386 from ~~$2,880,884~~$1,448,132 for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 to ~~$2,508,895~~$3,650,518 for the ~~nine~~six months ended ~~September~~June 30, ~~2019.~~2020. The ~~decrease was primarily the result~~increase in general and administrative expenses resulted from an increase of ~~a decrease of $929,483 in consulting fees and a decrease of $64,978 in legal fees that were partially offset by increases of $292,939~~$888,572 in other professional services, ~~$87,631~~and increase of $514,266 in ~~option~~bad debt expense as an allowance for bad debts was established due to the significant increase in receivables. Additionally, stock-based compensation expense related to options and ~~warrant expense, $77,245 in insurance expenses, $79,616 in salary~~warrants increased by $488,920 due to options granted to employees and directors, salaries and related benefits increased by $112,935, attorneys’ fees increased by $54,001 and ~~$58,398 in travel expenses.~~a 401K contribution of $40,600 was also incurred.

Our sales and marketing expenses for the ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 were ~~$770,539~~$658,674 compared to sales and marketing expenses of ~~$419,410~~$508,179 for the ~~nine~~six months ended ~~September~~June 30, ~~2018.~~2019. The increase of ~~$351,129~~$150,495 was ~~due primarily to~~the result of an increase in salaries and related benefits of $131,903, an increase of ~~$167,783~~$23,966 in ~~salary~~advertising and ~~related benefits expense, an increase of $88,762 in travel and convention expenses,~~trade shows, and an increase of ~~$81,864~~$21,600 for a 401K contribution. These increases were partially offset by a decrease in ~~consulting expenses.~~travel and related expenses of $43,462 as travel was curtailed by the current pandemic.

Our research and development expenses increased by ~~only $5,197~~$490,376 from ~~$985,726~~$659,896 for the ~~nine~~six months ended ~~September 30, 2018~~June 20, 2019 to ~~$990,923~~$1,150,271 for the ~~nine~~six months ended ~~September~~June 30, ~~2019.~~2020. The increase ~~reflected, however,~~was primarily due to an increase of ~~$131,288 in payroll and employee related expenses from the addition of more lab employees, partially offset by a decrease of $58,234 in consulting expenses and a decrease of $51,546~~$193,117 in other ~~professional~~profession services related to development of the capability of freeze drying our COVID-19 test to enable easier international shipping. In addition, salaries and ~~a decrease of $17,581 in~~related benefits increased $113,946 reflecting additional lab ~~supplies.~~personnel, expenditures for lab supplies increased $89,252, our 401K contribution increased by $37,800, and the rent for lab space increased $34,929.

Interest Expense

For the ~~nine~~six months ended ~~September~~June 30, 2020, we incurred no interest expense compared to interest expense for the six months ended June 30, 2019 ~~we incurred interest expense~~ of ~~$28,196 compared to $48,857 for the nine months ended September 30, 2018.~~$28,187. The decrease of ~~$20,661 was~~$28,187was the result of having ~~all~~a $2,000,000 loan outstanding during the month of ~~our indebtedness retired~~January 2019 for which we incurred $28,187 in interest. Additionally, we incurred a loss of $78,241 on extinguishment of debt incident to the ~~conversion of our debt in January 2019 to preferred stock and having no debt for the majority~~payoff of the ~~nine-month period~~loan referenced herein. For the six months ended ~~September~~June 30, ~~2019. We realized~~2020 we recorded interest income of ~~$32,255~~$45,748 from ~~the investment of funds~~interest on our cash not used in the operations of the business compared to interest income of ~~$17,361~~$20,049 for the ~~nine~~six months ~~ended September~~ending June 30, ~~2018.~~2019

Net ~~Loss~~Income

We realized a net ~~loss~~income for the ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 of ~~$4,460,551~~$13,939,816 compared with a net loss for the ~~nine~~six months ended ~~September~~June 30, ~~2018~~2019 of ~~$4,323,555.~~$2,712,785. The increase in net ~~loss~~income of ~~$136,996~~$16,652,601 was primarily the result of ~~realizing an increased loss~~sales of ~~$119,383 on~~ our ~~investment in~~LogixSmart COVID-19 test and resulting margins from those sales. In addition, we realized income from our Indian joint venture ~~and~~of $267,740 compared to a loss onin the ~~extinguishment~~joint venture of ~~debt of $78,241 incident to~~$7,000 in the ~~retirement of our outstanding debt in January~~six months ending June 30, 2019 ~~when the debt was converted of preferred stock. The increase in loss occasioned by the extinguishment of debt and the loss in~~as our joint venture ~~was partially offset by~~began sales of the ~~increase~~Saragene COVID-19 test after clearance to begin manufacture and sale of the test in ~~interest income and~~India. The sales in India were primarily made in the ~~decrease in interest expense.~~month of June.

~~Results of Operations for~~The three months ended June 30, 2020 compared to the ~~Three Months~~three months ended ~~September~~June 30, 2019 ~~and 2018~~

~~Net Sales~~Revenues
For the three months ending June 30, 2020 we generated revenues of $24,040,274 compared to revenues of $61,574 for the three months ending June 30, 2019. The revenue in the quarter ending June 30, 2020 primarily represented sales of our LogixSmart COVID-19 test. Of the total revenue in the three months ending June 30, 2020, $1,676,820 related to the sale of third party manufactured equipment, which we source and sold to customers to facilitate the sales of our COVID-19 test.
Cost of Revenues

For the three months ended ~~September~~June 30, ~~2019,~~2020 we ~~generated $41,434~~recorded costs of ~~net sales compared to net sales~~revenues of ~~$9,696 in~~$5,975,305 and for the three months ended September 30, 2018. The revenue in 2019 represented sales of our diagnostics tests as well as fees charged for design services and $14,000 of which was for the sale of equipment. The revenue in 2018 represented a license fee for licensing our Zika tests and certain other Flaviviruses to a Canadian company for limited distribution. This license fee has since been terminated.
~~Cost of Sales~~
~~For the three months ended September~~June 30, 2019, we recorded costs of ~~sales~~revenues of ~~$20,365 related~~$38,809. This increase is due to the ~~tests and equipment sold. For~~increase in revenue in 2020 due to the ~~three months ended September 30, 2018, we recorded no~~sale of our LogixSmart COVID-19 test. Of the total cost of ~~sales.~~sale, $1,580,968 was due to equipment that was sold to our customers.
28
~~Operating~~ Expenses

We incurred total operating expenses of ~~$1,671,156~~$3,356,692 for the three months ended ~~September~~June 30, ~~2019~~2020, compared to total operating expenses of ~~$1,673,465~~$1,388,529 for the three months ended ~~September~~June 30, ~~2018.~~2019. The ~~decrease~~increase of ~~$2,309 actually reflected progress in our business plan in that our sales and marketing expenses~~$1,968,163 was due primarily to increased ~~by $82,103 representing increased emphasis in selling diagnostics tests that are ready for general distribution, which increases were offset by~~ general and administrative ~~expenses that decreased $89,407. Research~~costs of $1,383,264, and an increase of $437,659 in our research and development ~~expenses remained constant.~~expenses.

General and administrative expenses ~~decreased $89,407~~increased $1,383,265, from ~~$1,150,170~~$807,769 for the three months ended ~~September~~June 30, ~~2018~~2019 to ~~$1,060,763~~$2,191,034 for the three months ended ~~September~~June 30, ~~2019.~~2020. The ~~decrease~~increase was primarily the result of ~~a decrease~~an increase of ~~$219,106 for consulting~~$511,607 in other professional services expense, an increase $483,266 in bad debt expense reserves and ~~a decrease~~an increase of ~~$126,647~~$175,085 in option and warrant ~~expenses. These decreases were partially offset by an~~expense. The increase in option expense was primarily related to, vesting of ~~$197,295~~options granted in ~~other professional services and to a lesser extent by smaller increases~~the third quarter of 2019, which had not been outstanding in the second quarter of 2019. In addition, salaries and other benefits increased $68,421, a contribution to our 401K of ~~$34,327, insurance of $21,722~~$40,600 and ~~travel expenses of $28,899.~~attorney fees increased $35,858.

Our sales and marketing expenses for the three months ended ~~September~~June 30, ~~2019~~2020 were ~~$262,360~~$390,191, compared to sales and marketing expenses of ~~$180,257~~$252,076 for the three months ended ~~September~~June 30, ~~2018.~~2019. The increase of ~~$82,103 was~~$138,115 is due primarily to an increase of ~~$30,940~~$114,394 in salary and related benefits expense ~~related to the addition of sales personnel, an increase of $43,992 in advertising, trade shows and related travel~~ and an increase of ~~$8,524~~$21,600 in ~~consulting~~401K contributions, an increase of $10,467 in advertising expense partially offset by a decrease of $30,004 in travel and lodging. The reduction of travel related expenses ~~for sales professionals in other countries. In addition, we incurred expenses of $5,947 specifically in acquiring and training our distributor network in other countries.~~was directly related to a ban on travel due to the coronavirus pandemic.

Our research and development expenses ~~remained constant. We incurred research and development expenses of $330,422~~increased by $437,659, from $312,590 for the three months ended ~~September~~June 30 ~~2018 and $331,027~~2019 to $750,249 for the three months ended ~~September~~June 30, ~~2019.~~2020. The increase was primarily due to an increase of $191,292 in payroll and employee related expenses resulting from the addition of technical personnel and $196,226 in other professional services related to a development contract for the freeze drying of our tests to facilitate international shipping. In addition, lab supplies increased by $56,792 and the 401K contribution for lab employees increased by $37,800.

~~Interest~~ Other Income/Expense

For the three months ended ~~September~~June 30, ~~2019,~~2020 we ~~incurred minimal interest expense~~had total other income of $296,732 compared to ~~interest expense~~a total other income of ~~$48,857~~$21,368 for the three months ended ~~September~~June 30, ~~2018.~~2019. The ~~decrease~~increase of ~~$48,847~~$275,364 was due to a gain of $258,559 from our India joint venture compared to a gain of $1,728 in the ~~result of having no debt~~same period in 2019 ~~compared to having a short term note~~and an increase of ~~$2,000,000 outstanding beginning~~$18,533 in ~~August 2018. We also realized~~ interest income ~~of $12,207 from the investment of funds not used~~ in the ~~operations of the business.~~three months ended June 30, 2020.

Net ~~Loss~~Income

We realized a net ~~loss~~income for the three months ended ~~September~~June 30, ~~2019~~2020 of ~~$1,747,766~~$15,005,009, compared with a net loss for the three months ended ~~September~~June 30, ~~2018~~2019 of ~~$1,641,145.~~$1,344,396. The income realized was due to the increase in ~~net loss~~gross profit realized from sales of ~~$106,621 was primarily the result of realizing a loss of $109,876 from~~ our ~~Indian joint venture compared to a gain of $67,961 reported~~LogixSmart COVID-19 test commencing in ~~2018 due to audit adjustments recorded by Indian joint venture. The increase in net loss was~~March 2020, partially offset by the ~~decrease~~increase in ~~interest~~operating expenses of $1,968,163 as explained above and the realization of increased interest income. Since operational expenses did not vary materially from year to year, the increase of net loss was primarily the result of non-operating activities.above.
19

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.

~~To date we have financed our operations through sales of common stock and the issuance of debt.~~
At ~~December 31, 2018,~~June 30, 2020, we had cash and cash equivalents of ~~$950,237,~~$18,550,437, total current assets of ~~$1,051,913,~~$36,901,648, total current liabilities of $2,351,983 and total stockholders’ deficit of $1,058,811. At September 30, 2019, we had cash and cash equivalents of $2,544,159, total current assets of $3,084,448, total current liabilities of $307,884$2,984,642 and total stockholders’ equity of ~~$3,333,995.~~
~~On January 30, 2019,~~$35,726,862. We believe that we entered into a securities purchase agreement with investors, whereby the investors purchased from the Company 30,000 shares of Series A Convertible Preferred Stock of the Company for a purchase price of $3,000,000. The purchase price was paid by the investors with $1.0 million in cash and the conversion of a $2.0 million note owed by the Companyhave sufficient capital to the investors. The investors may not convert the Series A Preferred Stock to the extent that such conversion would result in beneficial ownership by the investors and their affiliates of more than 4.99% of the issued and outstanding Common Stock of the Company.
On February 4, 2019, we completed the sale of 3,925,716 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $1.40 per share in a registered direct offering. The aggregate gross proceedssustain our operations for the ~~sale of the Common Shares was $5,496,002 and we received net proceeds of $4,903,238 after offering costs of $592,764.~~next 12 months.

We experienced negative cash flow used in operations during the ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 of ~~$3,912,850~~$348,459, compared to negative cash flow used in operations for the ~~nine~~six months ended ~~September 30, 2018 of $3,119,401. During the nine months ended September~~June 30, 2019 of $2,697,691. The cash generated from operations enabled us to increase our inventories by $10,030,838 and ~~2018,~~increase our receivables by $5,742,883. In addition, we ~~received net cash from financing activities of $5,903,238 and $1,899,012 as described above and~~ used ~~$319,440 and $135,000, respectively~~$1,457,922 of our cash in financing transactions, $714,500 in contributions to our joint venture in ~~India.~~India and $205,290 for the purchase of equipment. The negative operating cash flow infor the ~~quarter~~six months ending June 30, 2020 was met by cash reserves received from ~~the issuances of common stock incident to~~ the completion of a series of three registered direct ~~offering~~offerings in January and February 2020 pursuant to our shelf registration. We received net proceeds of $18,062,083 from those offerings and received $913,465 from the ~~issuance~~exercise of ~~preferred stock~~warrants and options. Since we commenced significant sales of our Logix Smart COVID-19 test in ~~January.~~March 2020, we have used our cash generated from those sales to fund the increase in our inventories and receivables and pay our operating expenses. We have increased our technical staff to complete development of additional tests to enable us to use our distributor network to sell our other products throughout the world. The amount of ~~our~~a future operating deficit could ~~decrease or increase significantly~~occur depending on strategic and other operating decisions, thereby affecting our need for additional capital. ~~We expect our operating losses will continue until~~If needed, we are able to generate material revenue. Until our operations become profitable, we will continue to rely on proceeds received from our offerings of stock. In August 2018 we filed a shelf registration of our securities with the SEC and in September 2018 it was declared effective. In February 2019 we completed the registered direct offering described above pursuant to that registration. We expect additional investment capital to come from (i) additional issuances of our common stock ~~pursuant to our S-3 shelf registration~~ with existing and new investors and (ii) the private placement of other securities with investors similar to those that have provided funding in the past.

29
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses and has not demonstrated the ability to generate sufficient cash flows from operations to satisfy our liabilities and sustain operations. These factors raise substantial doubt about our ability to continue as a going concern. Our continuation as a going concern is dependent on our ability to generate sufficient income and cash flow to meet our obligations on a timely basis and to obtain additional financing as may be required. The Company is actively seeking options to obtain additional capital and financing.

Our monthly cash operating expenses, including our technology research and development expenses and interest expense, were approximately ~~$435,000~~$686,200 per month during the ~~nine~~six months ~~ended September~~ending June 30, ~~2019.~~2020. We completed the registered direct offering described above in January and February 2020 to fund operations through 2020. The foregoing estimates, expectations and forward-looking statements are subject to change as we make strategic operating decisions from time to time and as our expenses fluctuate from period to period.

To date, we have financed our operations through sales of our LogixSmart COVID-19 test and sales of common stock and the issuance of debt.
● On January 30, 2019, we entered into a securities purchase agreement with investors, whereby the investors purchased from the Company an aggregate of 30,000 shares of Series A Convertible Preferred Stock of the Company for an aggregate purchase price of $3,000,000. The purchase price was paid by the investors with $1 million in cash and the conversion of a $2 million promissory note issued by the Company to one of the investors. All of the preferred shares have been converted to common stock.
● On February 4, 2019, we completed the sale of an aggregate of 3,925,716 shares of common stock, at a purchase price of $1.40 per share in a registered direct offering pursuant the Shelf Registration Statement. The aggregate gross proceeds for the sale of the shares were $5,496,002 and we received net proceeds after offering costs of $4,996,322.
● In January 2020, we sold an aggregate of 3,448,278 shares of common stock to institutional investors for $1.45 per share for gross proceeds of approximately $5 million pursuant to a shelf-registration statement on Form S-3 (File No: 333-226835) declared effective by the SEC on September 7, 2018 (the “Shelf Registration Statement”).
● On February 10, 2020, the Company entered into securities purchase agreements with certain institutional investors pursuant to which such investors purchased an aggregate of 3,324,676 shares of common stock at a purchase price of $ 3.08 per share in a registered direct offering pursuant to the Shelf Registration Statement. The aggregate gross proceeds for the sale of the shares were approximately $10.2 million. The closing of the offering occurred on or about February 13, 2020.
● On February 28, 2020, the Company entered into securities purchase agreements with certain institutional investors pursuant to which such investors purchased an aggregate of 470,000 shares of common stock at a purchase price of $9.00 per share in a registered direct offering pursuant to the Shelf Registration Statement. The aggregate gross proceeds for the sale of the shares were approximately $4 million. The closing of the offering occurred on or about February 28, 2020.
●
On March 6, 2020, we received $50,000 in gross proceeds from the exercise of a warrant for 25,000 shares of common stock for $2.00 per share.
During the three months ending June 30, 2020, we received $863,465 from the exercise of warrants and stock options.
● We generated $13,939,816 in net income during the six months ending June 30, 2020 to fund our operations.
The amount of our operating ~~deficit~~income going forward could decrease or increase significantly depending on strategic and other operating decisions, thereby affecting our need for additional capital. We ~~expect~~have increased our ~~operating losses will continue until we~~work force and are ~~able~~using the increased technical staff to ~~generate revenue. Sales~~complete development on products related to the current pandemic and ~~marketing efforts have resulted~~on products unrelated thereto in ~~revenue being generated from sales of our diagnostics products in India, South and Central America and for our mosquito vector control program~~an attempt to remain profitable in the ~~United States. The amount~~future. At our current level of ~~revenue from these and other revenue sources will determine~~operating expenditures, we believe we have sufficient cash to fund operations for the ~~amount of~~next 12 months. Absent a significant acquisition or capital expansion, we do not expect to require additional ~~investment needed to bridge~~capital in the ~~gap until we achieve a breakeven status.~~foreseeable future.
Our long-term liquidity is dependent upon execution of our business model and the ~~increase~~commencement of revenue generating activities and working capital as described above, and upon capital needed for continued commercialization and development of our diagnostic testing technology. Commercialization and future development of diagnostic tests utilizing our PCR technology are expected to require additional capital annually for the foreseeable future. The amount required will increase or decrease depending on the opportunities we determine to pursue and available funding.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.
30

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not required under Regulation S-K for “smaller reporting companies.”

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain ~~a set of disclosure~~“disclosure controls and procedures, ~~(as~~” as defined in ~~Rule~~Rules 13a-15(e) ofand 15d-15(e) under the Exchange ~~Act)~~Act that are designed to ensure that information required to be disclosed by a company in ~~reports filed or submitted under~~ the ~~Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC.~~
In accordance with Rule 13a-15(b) of the Exchange Act, as of the end of the period covered by this quarterly report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, to assess the effectiveness of our disclosure controls and procedures. As of the end of the period covered by this quarterly report on Form 10-Q our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by us in reports that ~~we file~~it files or ~~submit~~submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and ~~forms~~forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to ~~our~~the company’s management, including ~~the Chief Executive Officer~~its principal executive and ~~Chief Financial Officer,~~principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

~~In performing its assessment~~At the time our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 was filed on August 14, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of ~~the effectiveness of the Company’s~~material weaknesses in our internal control over financial reporting ~~management applied~~as disclosed in our annual report on Form 10-K for the ~~criteria~~year ended December 31, 2019 and discussed below, our disclosure controls and procedures were not effective as of June 30, 2020. Subsequent to that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that an additional material weakness, as described ~~in the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO - 2013”).~~below, existed.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of ~~the Company’s~~our annual or interim financial statements will not be prevented or detected on a timely basis.

The material weakness previously identified during management’s assessment was the lack of sufficient technical expertise on certain accounting and tax requirements for new and unusual transactions. These control deficiencies could result in a material misstatement of accounts or disclosures that would result in a material misstatement to ~~the Company’s~~our interim or annual financial statements that would not be prevented or detected. ~~Accordingly, management has determined~~
In connection with the identification of an error that resulted in the restatement described in Note 3 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q/A, we also identified that we did not design and maintain effective controls over the purchasing and receiving of inventory. Specifically, there was a lack of formalized purchasing and receiving processes and controls and the functions were decentralized. This material weakness resulted in the restatement of our condensed consolidated financial statements for the quarterly period ended June 30, 2020.
To address the previously identified material weakness, we have involved and plan to further increase the involvement of consultants with the required expertise and have hired one employee and plan to further increase the accounting staff to remediate the material weakness. We believe that these ~~control deficiencies constitute a~~actions will help remediate the previously identified material weakness. The ~~Company hired, in~~weakness, however, will not be considered remediated until the ~~second quarter~~applicable controls operate for a sufficient period of ~~2019, consultants with~~time and management is able to conclude that these controls are operating effectively.
To address the ~~necessary technical accounting expertise to improve~~newly identified material weakness, we have centralized the ~~Company’s accounting~~purchasing and receiving functions and have added new processes and ~~internal control program. The Company has unconsolidated foreign subsidiaries over which it does not exercise any financial reporting control.~~
~~Because of the material weakness, management, including the Chief Executive Officer~~controls to ensure purchasing and ~~Chief Financial Officer, concluded that~~receiving are recorded completely and accurately. Additionally, the Company ~~did not maintain effective internal control over financial reporting as of September 30, 2019, based on~~is implementing a new enterprise resource planning (“ERP”) system, which will enable us to further enhance the ~~criteria in Internal Control-Integrated Framework issued by COSO -2013.~~processes and controls related to inventory, including purchasing and receiving.

Changes in Internal Control over Financial Reporting

~~There~~Other than the efforts noted above to remediate the previously reported material weaknesses, there have been no changes in ~~the Company’s~~our internal control over financial reporting ~~(as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred~~ during the ~~Company’s last three-month period~~quarter ended June 30, 2020 that ~~have~~has materially affected or, are reasonably likely to materially affect, ~~the Company’s~~our internal control over financial reporting. The Company hired an independent consulting company to render a report on the Company’s internal control systems and provide recommendations for improving our internal control given the size of the Company’s accounting staff. To the extent possible with the current accounting staff the internal control recommendations have been implemented.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

On July 16, 2020, we were served in an action filed in the United States District Court for the District of Utah claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The ~~Company~~Plaintiff, Gelt Trading, Ltd., a Cayman Islands limited company, demands compensatory damages sustained as a result of our alleged wrongdoing in an amount to be proven at trial. We will vigorously defend this action as we do not believe it has ~~no legal proceedings~~any merit.
In addition, there is a threatened lawsuit from former consultants claiming compensation for services rendered in 2015. We will vigorously defend this matter if it results in a lawsuit.
From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. Although we have received inquiries from FINRA, NASDAQ and the SEC, to which we have responded, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of ~~management, no litigation has been threatened.~~our properties or businesses are subject, which would reasonably be likely to have a material adverse effect on the Company.
31

Item 1A. Risk Factors

~~Not~~Risks Related to Our Business and Industry
We have a limited commercial history upon which to base our prospects and until this calendar quarter, we have not generated profits and are not certain that we will sustain profitability in the future.
We began operations in April 2013, and we have a limited operating history. While we were profitable for the three- and six-month periods ended June 30, 2020, we realized a net loss for the three months ended March 31, 2020 of $1,065,193, and a net loss of $6.2 million and $6.3 million for the years ended December 31, 2019 and December 31, 2018, respectively. Our accumulated deficit was $11.0 million as of June 30, 2020 and $25.0 million and $18.7 million as of December 31, 2019 and December 31, 2018, respectively. We realized net income for the first time for the three months ended June 30, 2020. We were able to achieve net income because we were able to develop and market our LogixSmart COVID-19 test, but we do not have any way to predict how long our market for that test will continue. Potential investors should be aware of the difficulties normally encountered by a new enterprise, many of which are beyond our control, including substantial risks and expenses in the course of developing new diagnostic tests, establishing or entering new markets, organizing operations and marketing procedures. The likelihood of our success must be considered in light of these risks, expenses, complications and delays, and the competitive environment in which we operate. There is, therefore, nothing at this time upon which to base an assumption that our business plan will continue to prove successful, and we may not be able to generate significant revenue, raise additional capital or operate profitably. We will continue to encounter risks and difficulties frequently experienced by early commercial stage companies, including scaling up our infrastructure and headcount, and may encounter unforeseen expenses, difficulties or delays in connection with our growth. In addition, as a result of the start-up nature of our business, we can be expected to continue to sustain substantial operating expenses and may not be able to continue generating sufficient revenues to cover expenditures. Any investment in our company is therefore highly speculative and could result in the loss of any investment.
Our near-term success has been dependent on the market for our COVID-19 test and future success is dependent on continued demand for the COVID-19 test and upon our ability to develop and market other commercially accepted diagnostic tests.
Our future success will depend, in part, on the continued market for our LogixSmart COVID-19 test and upon our ability to develop and sell sufficient quantities of other diagnostics tests. Attracting new customers and distribution networks requires substantial time and expense. Any failure to continue sales of our tests in sufficient quantities to maintain profitability would adversely affect our operating results. Many factors could affect the market acceptance and commercial success of any of our diagnostic tests, including:
● Our ability to develop additional infectious disease diagnostic tests for which there is a commercial market.
● our ability to convince our potential customers of the advantages and economic value of our tests over competing technologies and diagnostic tests;
● the breadth of our test menu relative to competitors;
● changes to policies, procedures or currently accepted best practices in clinical diagnostic testing;
● the extent and success of our marketing and sales efforts; and
● our ability to manufacture in quantity our commercial diagnostic tests and meet demand in a timely fashion.
32
Risks Related to Owning our Common Stock and Other Securities
The price of our common stock may fluctuate substantially.
The market price of our common stock may be subject to wide fluctuation in response to various factors, some of which are beyond our control. Some factors that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this “Risk Factors” section and elsewhere in this report, are:
● sales of our common stock by our shareholders, executives, and directors;
● our ability to enter new markets;
● actual or un-anticipated fluctuations in our annual and quarterly financial results;
● our ability to obtain financings to continue and expand our commercial activities, expand our manufacturing operations, conduct research and development activities including, but not limited to, human clinical trials, and other business activities;
● our ability to secure resources and the necessary personnel to continue and expand our commercial activities, develop additional diagnostic tests, conduct clinical trials and gain approval for our diagnostic tests on our desired schedule;
● commencement, enrollment or results of our clinical trials of our diagnostic tests or any future clinical trials we may conduct;
● changes in the development status of our diagnostic tests;
● any delays or adverse developments or perceived adverse developments with respect to review by the FDA or other similar foreign regulatory authorities of our planned clinical trials;
● any delay in our submission for studies or test approvals or adverse regulatory decisions, including failure to receive regulatory approval for our diagnostic tests;
● our announcements or our competitors’ announcements regarding new tests, enhancements, significant contracts, acquisitions or strategic investments;
● failures to meet external expectations or management guidance;
● changes in our capital structure or dividend policy, including as a result of future issuances of securities and sales of large blocks of common stock by our shareholders;
● announcements and events surrounding financing efforts, including debt and equity securities;
● competition from existing technologies and diagnostic tests or new technologies and diagnostic tests that may emerge;
● announcements of acquisitions, partnerships, collaborations, joint ventures, new diagnostic tests, capital commitments, or other events by us or our competitors;
● changes in general economic, political and market conditions in any of the regions in which we conduct our business;
● changes in industry conditions or perceptions;
● changes in valuations of similar companies or groups of companies;
● analyst research reports, recommendations and changes in recommendations, price targets and withdrawals of coverage;
● departures and additions of key personnel;
● disputes and litigations related to intellectual properties, proprietary rights, and contractual obligations;
● changes in applicable laws, rules, regulations, or accounting practices and other dynamics;
● actions taken by our principal shareholders and release or expiry of lockup or other transfer restrictions; and
● other events or factors, many of which may be out of our control.
In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.
Future sales of our common stock in the public market may cause our stock price to decline and impair our ability to raise future capital through the sale of our equity securities.
There are a substantial number of shares of our common stock held by shareholders who owned shares of our capital stock prior to our initial public offering that may be able to sell in the public market. Sales by such shareholders of a substantial number of shares could significantly reduce the market price of our common stock.
33
Shares issued by us upon exercise of options granted under our equity plan will be eligible for sale in the public market. If any of these holders cause a large number of securities to be sold in the public market, the sales could reduce the trading price of our common stock. These sales also could impede our ability to raise capital in the future.
Anti-takeover provisions in our charter documents and Utah law could discourage delay or prevent a change of control of our Company and may affect the trading price of our common stock.
We are a Utah corporation and the anti-takeover provisions of the Utah Control Shares Acquisition Act may discourage, delay or prevent a change of control by limiting the voting rights of control shares acquired in a control share acquisition. In addition, our Articles of Incorporation and Bylaws may discourage, delay or prevent a change in our management or control over us that shareholders may consider favorable. Among other things, our Amended and Restated Articles of Incorporation and Bylaws:
● authorize the issuance of “blank check” preferred stock that could be issued by our board of directors in response to a takeover attempt;
● provide that vacancies on our board of directors, including newly created directorships, may be filled only by a majority vote of directors then in office, except a vacancy occurring by reason of the removal of a director without cause shall be filled by vote of the shareholders; and
● limit who may call special meetings of shareholders.
These provisions could have the effect of delaying or preventing a change of control, whether or not it is desired by, or beneficial to, our shareholders.
NASDAQ may delist our common stock from its exchange, which could limit investors’ ability to make transactions in our common stock and subject us to additional trading restrictions.
Should we fail to satisfy the continued listing requirements of the NASDAQ Capital Market, such as the corporate governance requirements or the minimum closing bid price requirement, NASDAQ may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock, and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we would take actions to restore our compliance with the NASDAQ Capital Market’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the NASDAQ Capital Market’s minimum bid price requirement or prevent future non-compliance with the NASDAQ Capital Market’s listing requirements.
If the NASDAQ Capital Market does not maintain the listing of our securities for trading on its exchange, we could face significant material adverse consequences, including:
● a limited availability of market quotations for our securities;
● reduced liquidity with respect to our securities;
● a determination that our shares of common stock are “penny stock” which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;
● a limited amount of news and analyst coverage for our company; and
● decreased ability to issue additional securities or obtain additional financing in the future.
Therefore, it may be difficult for our shareholders to sell any shares if they desire or need to sell them.
34
We do not currently intend to pay dividends on our common stock
We do not expect to pay cash dividends on our common stock. Any future dividend payments are within the absolute discretion of our board of directors and will depend on, among other things, our results of operations, working capital requirements, capital expenditure requirements, financial condition, contractual restrictions, business opportunities, anticipated cash needs, provisions of applicable law and other factors that our board of directors may deem relevant. We may not generate sufficient cash from operations in the future to pay dividends on our common stock.
We are an “emerging growth company” and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Investors may find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an “emerging growth company.” We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (iii) the date on which we have issued more than $1.07 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under ~~Regulation S-K~~the rules of the Securities and Exchange Commission.
We have elected to use the extended transition periods for ~~“smaller reporting companies.”~~complying with new or revised accounting standards.
We have elected to use the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transaction period provided in Section 7(a)(2)(B). As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates.
Our management is required to devote substantial time to compliance initiatives.
As a public company, we incur significant legal, accounting and other expenses that we did not incur as a newly formed entity. The Sarbanes-Oxley Act, as well as rules subsequently implemented by the Securities and Exchange Commission, and NASDAQ, have imposed various new requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Our management and other personnel devote a substantial amount of time to these new compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time consuming and costly. We expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

~~In September 2019,~~We issued the unregistered securities below during the quarter ended June 30, 2020. For each of the issuances of unregistered securities, we issued 200,000 shares of our common stock to an individual who converted 2,400 shares of our Series A Preferred Stock to common stock at a conversion price calculated by multiplying the number of preferred shares being converted by $100 and dividing the result by $1.20. We relied on the exemption from registration ~~under~~requirements of the Securities Act of 1933, as amended, ~~set forth in~~available under Section 4(a)(2) ~~thereof and Regulation D~~ promulgated ~~thereunder.~~thereunder due to the fact that such issuances did not involve a public offering of securities.

On September 30, 2019, we issued 15,156 shares of our common stock to an entity that provides services for the Company pursuant to a written contract. We relied on the exemption from registration under the Securities Act of 1933, as amended, set forth in Section 4(a)(2) thereof and Regulation D promulgated thereunder.
● On April 1, 2020, we issued a warrant to acquire up to 20,000 shares of our common stock at an exercise price of $1.40. the warrant was issued to a consultant pursuant to our agreement with the consultant. The warrant has a five-year life.
● On June 30, 2020, we issued an aggregate of 9,689 shares of our common stock for services rendered pursuant to consulting agreements.
● In June 2020, we issued 110,000 shares of stock pursuant to the exercise of warrants at an exercise price of $2.00 to three individuals and one limited liability company.

35
On September 30, 2019, we issued 6,000 shares of our common stock to an entity that provides services for the Company pursuant to a written contract. We relied on the exemption from registration under the Securities Act of 1933, as amended, set forth in Section 4(a)(2) thereof and Regulation D promulgated thereunder.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

~~None.~~Subsequent Events
In August, 2020, we discovered that a freezer that held manufactured tests had failed and that approximately $1,200,000 of finished goods inventory had thawed and was no longer saleable and will be written off.

Item 6. Exhibits

Exhibit Index

(a) Exhibits

Exhibit Number ~~Number~~ Description

31.1* Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2* Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1* Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2* Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Extension Label Linkbase Document
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File

* Filed herewith.

22 36

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CO-DIAGNOSTICS, INC.

Date: November ~~12, 2019~~3, 2020 By: /s/ Dwight H. Egan
Name: Dwight H. Egan
~~Its:~~Title:
President and Chief Executive Officer
(Principal Executive Officer)

Date: November ~~12, 2019~~3, 2020 By: /s/ Reed LL. Benson
Name: Reed LL. Benson
~~Its:~~Title:
Chief Financial Officer
(Principal Financial and Accounting Officer)
37

	September 30, 2019			December 31, 2018
ASSETS:
Current Assets
Cash and cash equivalents	$	2,544,159		$	950,237
Accounts receivables, net		60,353			13,420
Inventory		17,353			18,153
Prepaid expenses		462,583			70,103
Total current assets		3,084,448			1,051,913
Other Assets
Property and equipment, net		179,746			156,138
Investment in joint venture		547,685			345,121
Total other assets		727,431			501,259

Total assets	$	3,811,879		$	1,553,172

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT):

Current Liabilities
Accounts payable	$	21,760		$	148,967
Accrued expenses		161,738			174,444
Accrued expenses (related party)		120,000			120,000
Deferred income		4,386			—
Notes payable net of discount of $0 and $91,428		—			1,908,572
Total current liabilities		307,884			2,351,983
Long-term Liabilities, net of current portion
Accrued expenses-long-term (related party)		170,000			260,000
Total long-term liabilities, net of current portion		170,000			260,000
Total liabilities		477,884			2,611,983

Commitments and contingencies

STOCKHOLDERS’ EQUITY (DEFICIT):
Convertible preferred stock, $.001 par value; 5,000,000 shares authorized, 25,600 and no shares issued and outstanding, respectively		26			—

Common stock, $.001 par value, 100,000,000 shares authorized; 17,336,922 and 12,923,383 shares issued and outstanding, respectively.		17,337			12,923
Additional paid-in capital		26,471,376			17,622,433
Accumulated deficit		(23,154,718	)		(18,694,167	)
Total stockholders’ equity (deficit)		3,333,995			(1,058,811	)

Total liabilities and stockholders’ equity (deficit)	$	3,811,879		$	1,553,172

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2019			2018			2019			2018
Net sales	$	41,434		$	9,696		$	106,408		$	29,088
Cost of sales		20,365			—			59,626			—
Gross profit		21,069			9,696			46,782			29,088
Operating expenses:
Sales and marketing		262,360			180,257			770,539			419,410
Administrative and general		1,060,763			1,150,170			2,508,895			2,880,884
Research and development		331,027			330,422			990,923			985,726
Depreciation and amortization		17,006			12,616			46,768			37,634
Total operating expenses		1,671,156			1,673,465			4,317,125			4,323,654
Loss from operations		(1,650,087	)		(1,663,769	)		(4,270,343	)		(4,294,566	)
Other expense:
Interest income		12,207			3,520			32,255			17,361
Interest expense		(10	)		(48,857	)		(106,437	)		(48,857	)
Gain on disposition of assets		—			—			850			—
Gain (loss) on equity method investment in joint venture		(109,876	)		67,961			(116,876	)		2,507
Total other expense		(97,679	)		22,624			(190,208	)		(28,989	)
Loss before income taxes		(1,747,766	)		(1,641,145	)		(4,460,551	)		(4,323,555	)
Provision for income taxes		—			—			—			—
Net loss	$	(1,747,766	)	$	(1,641,145	)	$	(4,460,551	)	$	(4,323,555	)

Basic and diluted income (loss) per common share	$	(0.10	)	$	(0.13	)	$	(0.27	)	$	(0.35	)

Weighted average common shares outstanding, basic and diluted		17,328,787			12,326,316			16,809,085			12,341,482

	Three Months Ended June 30, 2020					Six Months Ended June 30, 2020
	2020		2019			2020		2019
	(Restated)					(Restated)
Net revenue	$	24,040,274	$	61,574		$	25,588,802	$	64,974
Cost of revenue		5,975,305		38,809			6,457,045		39,261
Gross profit		18,064,969		22,765			19,131,757		25,713
Operating expenses
Sales and marketing		390,191		252,076			658,674		508,179
Administrative and general		2,191,034		807,769			3,650,518		1,448,132
Research and development		750,249		312,590			1,150,271		659,896
Depreciation and amortization		25,218		16,094			45,966		29,762
Total operating expenses		3,356,692		1,388,529			5,505,429		2,645,969
Income (loss) from operations		14,708,277		(1,365,764	)		13,626,328		(2,620,256	)
Other income (expense)
Interest income		38,173		19,640			45,748		20,048
Interest expense		-		-			-		(106,427	)
Gain on disposition of assets		-		-			-		850
Gain (loss) on equity method investment in joint venture		258,559		1,728			267,740		(7,000	)
Total other income (expense)		296,732		21,368			313,488		(92,529	)
Income (loss) before income taxes		15,005,009		(1,344,396	)		13,939,816		(2,712,785	)
Provision for income taxes		-		-			-		-
Net income (loss)	$	15,005,009	$	(1,344,396	)	$	13,939,816	$	(2,712,785	)
Net income (loss) per common share:
Basic	$	0.54	$	(0.08	)	$	0.50	$	(0.16	)
Diluted	$	0.51	$	(0.08	)	$	0.48	$	(0.16	)
Weighted average shares outstanding:
Basic		27,582,229		17,017,964			27,605,137		17,017,964
Diluted		29,152,222		17,017,964			29,094,475		17,017,964

	Nine Months Ended September 30,
	2019			2018
Cash flows from operating activities:
Net loss	$	(4,460,551	)	$	(4,323,555	)
Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization		46,768			37,634
Stock based compensation		570,632			570,385
Accretion of notes payable discount		91,428			—
Gain on disposition of assets		(850	)		—
Loss (gain) of equity method investment		116,876			(2,507	)
Changes in assets and liabilities:
Increase in accounts and other receivables		(39,433	)		—
Increase (decrease) in deferred income		4,386			(29,088	)
(Increase) decrease in prepaid and other assets		(12,993	)		694,036
Decrease in inventory		800			—
Decrease in accounts payable and accrued expenses		(229,913	)		(66,306	)

Net cash used in operating activities		(3,912,850	)		(3,119,401	)

Cash flows from investing activities:
Purchase of property and equipment		(77,026	)		(2,500	)
Investment in joint venture		(319,440	)		(135,000	)

Net cash used by investing activities		(396,466	)		(137,500	)

Cash flows from financing activities:
Proceeds from sale of common stock		5,496,002			30,000
Proceeds from sale of preferred stock		1,000,000			—
Proceeds from the issuance of debt		—			2,000,000
Payment of offering costs		(592,764	)		(130,988	)

Net cash provided by financing activities		5,903,238			1,899,012

Net increase (decrease) in cash		1,593,922			(1,357,889	)

Cash and cash equivalents beginning of period		950,237			3,534,454

Cash and cash equivalents end of period	$	2,544,159		$	2,176,565

Supplemental disclosure of cash flow information:
Interest paid	$	15,000		$	26,000
Income taxes paid	$	—		$	—
Schedule of non-cash investing and financing activities:
Warrants issued for services	$	379,487			—
Conversion of preferred stock to common	$	440,000		$	—
Conversion of debt for preferred stock	$	2,000,000		$	—

	Six Months Ended June 30,
	2020			2019
	(Restated)
Cash flows from operating activities
Net income (loss)	$	13,939,816		$	(2,712,785	)
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation and amortization		45,966			29,762
Stock-based compensation expense		1,124,242			294,677
Accretion of notes payable discount		-			91,428
Gain on disposition of assets		-			(850	)
Loss (gain) from equity method investment		(267,740	)		7,000
Changes in assets and liabilities:
Accounts and other receivable		(5,218,494	)		(42,065	)
Prepaid and other assets		(2,527,983	)		(183,446	)
Inventory		(10,030,838	)		9,920
Deffered revenue		1,044,225			-
Accounts payable and accrued expenses		1,542,347			(191,332	)
Net cash used in operating activities		(348,459	)		(2,697,691	)
Cash flows from investing activities
Purchase of property and equipment		(205,290	)		(52,775	)
Investment in joint venture		(714,500	)		(247,000	)
Net cash used in investing activities		(919,790	)		(299,775	)
Cash flows from financing activities
Proceeds from sale of common stock		19,470,005			5,496,002
Proceeds from sale of preferred stock		-			1,000,000
Proceeds from exercise of options and warrants		913,465			-
Payment of offering costs		(1,457,922	)		(592,764	)
Net cash provided by financing activities		18,925,548			5,903,238
Net increase in cash and cash equivalents		17,657,299			2,905,772
Cash and cash equivalents at beginning of period		893,138			950,237
Cash and cash equivalents at end of period	$	18,550,437		$	3,856,009
Supplemental disclosure of cash flow information
Interest paid	$	-		$	15,000
Income taxes paid	$	-		$	-
Supplemental disclosure of non-cash investing and financing transactions
Inventory moved to property, plant and equipment	$	117,220		$	-

	Convertible Preferred Stock						Common Stock				Additional Paid-In-			Accumulated			Total Stockholders’ Equity			Convertible Preferred Stock						Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
																				Shares			Amount			Shares		Amount		Capital			Deficit			Equity
Balance as of December 31, 2019																					25,600		$	26			17,342,922	$	17,343	$	26,687,701		$	(24,967,814	)	$	1,737,230
Public offering, net of offering costs of $1,457,922																					-			-			7,242,954		7,243		18,004,840			-			18,012,083
Issuance of common stock for warrant exercises																					-			-			719,492		720		49,280			-			50,000
Stock-based compensation expense																					-			-			12,363		12		432,811			-			432,823
Conversion of preferred stock to common																					(25,600	)		(26	)		2,133,333		2,133		(2,107	)		-			-
Net loss																					-			-			-		-		-			(1,065,193	)		(1,065,193	)
Balance as of March 31, 2020																					-		$	-			27,451,064	$	27,451	$	45,172,525		$	(26,033,007	)	$	19,166,943
Issuance of common stock for warrant exercises																					-			-			530,289		530		862,935			-			863,465
Stock-based compensation expense																					-			-			9,689		10		691,409			-			691,419
Net income																					-			-			-		-		-			15,005,009			15,005,009
Balance as of June 30, 2020																					-		$	-			27,991,042	$	27,991	$	46,726,869		$	(11,027,998	)	$	35,726,836
	Shares			Amount			Shares		Amount		Capital			Deficit			(Deficit)
Balance as of December 31, 2018		—		$	—			12,923,383	$	12,923	$	17,622,433		$	(18,694,167	)	$	(1,058,811	)		-		$	-			12,923,383	$	12,923	$	17,622,433		$	(18,694,167	)	$	(1,058,811	)
Public offering, net of offering costs of $592,764		—			—			3,925,716		3,926		4,899,312			—			4,903,238			-			-			3,925,716		3,926		4,899,312			-			4,903,238
Issuance of Preferred Stock		30,000			30			—		—		2,999,970			—			3,000,000
Issuance of preferred stock																					30,000			30			-		-		2,999,970			-			3,000,000
Stock-based compensation expense		—			—			—		—		87,794			—			87,794			-			-			-		-		87,794			-			87,794
Conversion of Preferred Stock to Common		(2,000	)		(2	)		166,667		167		(165	)		—			—
Conversion of preferred stock to common																					(2,000	)		(2	)		166,667		167		(165	)		-			-
Net loss		—			—			—		—		—			(1,368,389	)		(1,368,389	)		-			-			-		-		-			(1,368,389	)		(1,368,389	)
Balance as of March 31, 2019		28,000		$	28			17,015,766	$	17,016	$	25,609,344		$	(20,062,556	)	$	5,563,832			28,000		$	28			17,015,766	$	17,016	$	25,609,344		$	(20,062,556	)	$	5,563,832

Stock-based compensation		—			—			—		—		505,970			—			505,970
Stock-based compensation expense																					-			-			-		-		505,970			-			505,970
Issuance of common stock for services		—						100,000		100		80,300						80,400			-			-			100,000		100		80,300			-			80,400
Net loss		—			—			—		—		—			(1,344,396	)		(1,344,396	)		-			-			-		-		-			(1,344,396	)		(1,344,396	)
Balance as of June 30, 2019		28,000		$	28			17,115,766	$	17,116	$	26,195,614		$	(21,406,952	)	$	4,805,806			28,000		$	28			17,115,766	$	17,116	$	26,195,614		$	(21,406,952	)	$	4,805,806

Stock-based compensation		—			—			—		—		253,798			—			253,798
Issuance of common stock for services		—						21,156		21		22,136			—			22,157
Conversion of Preferred Stock to Common		(2,400	)		(2	)		200,000		200		(198	)		—			—
Net loss		—			—			—		—		—			(1,747,766	)		(1,747,766	)
Balance as of September 30, 2019		25,600		$	26			17,336,922	$	17,337	$	26,471,350		$	(23,154,718	)	$	3,333,995

	June 30, 2020
	As Previously Reported			Adjustments		As Restated

Assets
Current assets
Cash and cash equivalents	$	18,550,437		$	-	$	18,550,437
Accounts receivable, net		5,349,876			-		5,349,876
Inventory		10,110,786			-		10,110,786
Prepaid expenses		521,180			2,369,369		2,890,549
Total current assets		34,532,279			2,369,369		36,901,648
Property and equipment, net		473,376			-		473,376
Investment in joint venture		1,416,480			-		1,416,480
Total assets	$	36,422,135		$	2,369,369	$	38,791,504
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	1,127,709		$	-	$	1,127,709
Accrued expenses		691,385			-		691,385
Accrued expenses (related party)		120,000			-		120,000
Deferred revenue		1,045,548			-		1,045,548
Total current liabilities		2,984,642			-		2,984,642
Accrued expenses-long-term (related party)		80,000			-		80,000
Total liabilities		3,064,642			-		3,064,642
Commitments and contingencies (Note 1)
Stockholders’ equity
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 25,600 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively		-			-		-
Common Stock, $0.001 par value; 100,000,000 shares authorized; 27,991,042 and 17,342,922 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively		27,991			-		27,991
Additional paid-in capital		46,726,869			-		46,726,869
Accumulated deficit		(13,397,367	)		2,369,369		(11,027,998	)
Total stockholders’ equity		33,357,493			2,369,369		35,726,862
Total liabilities and stockholders’ equity	$	36,422,135		$	2,369,369	$	38,791,504

	Three Months Ended June 30, 2020
	As Previously Reported		Adjustments			As Restated

Net revenue	$	24,040,274	$	-		$	24,040,274
Cost of revenue		8,344,674		(2,369,369	)		5,975,305
Gross profit		15,695,600		2,369,369			18,064,969
Operating expenses
Sales and marketing		390,191		-			390,191
Administrative and general		2,191,034		-			2,191,034
Research and development		750,249		-			750,249
Depreciation and amortization		25,218		-			25,218
Total operating expenses		3,356,692		-			3,356,692
Income from operations		12,338,908		2,369,369			14,708,277
Other income
Interest income		38,173		-			38,173
Interest expense		-		-			-
Gain on disposition of assets		-		-			-
Gain (loss) on equity method investment in joint venture		258,559		-			258,559
Total other income		296,732		-			296,732
Income before income taxes		12,635,640		2,369,369			15,005,009
Provision for income taxes		-		-			-
Net income	$	12,635,640	$	2,369,369		$	15,005,009
Net income per common share:
Basic	$	0.46	$	0.08		$	0.54
Diluted	$	0.43	$	0.08		$	0.51
Weighted average shares outstanding:
Basic		27,582,229		27,582,229			27,582,229
Diluted		29,152,222		29,152,222			29,152,222

	Six Months Ended June 30, 2020
	As Previously Reported		Adjustments			As Restated

Net revenue	$	25,588,802	$	-		$	25,588,802
Cost of revenue		8,826,414		(2,369,369	)		6,457,045
Gross profit		16,762,388		2,369,369			19,131,757
Operating expenses
Sales and marketing		658,674		-			658,674
Administrative and general		3,650,518		-			3,650,518
Research and development		1,150,271		-			1,150,271
Depreciation and amortization		45,966		-			45,966
Total operating expenses		5,505,429		-			5,505,429
Income (loss) from operations		11,256,959		2,369,369			13,626,328
Other income
Interest income		45,748		-			45,748
Interest expense		-		-			-
Gain on disposition of assets		-		-			-
Gain (loss) on equity method investment in joint venture		267,740		-			267,740
Total other income		313,488		-			313,488
Income before income taxes		11,570,447		2,369,369			13,939,816
Provision for income taxes		-		-			-
Net income	$	11,570,447	$	2,369,369		$	13,939,816
Net income per common share:
Basic	$	0.42	$	0.08		$	0.50
Diluted	$	0.40	$	0.08		$	0.48
Weighted average shares outstanding:
Basic		27,605,137		27,605,137			27,605,137
Diluted		29,094,475		29,094,475			29,094,475

	Options Outstanding		Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Contractual Life (years)
Outstanding at January 1, 2018		322,707	$	1.29	$	0.70		7.05
Options granted		850,000		2.63		1.24		9.98
Expired		—		—		—		—
Forfeited options		—		—		—		—
Exercised		—		—		—		—
Outstanding at December 31, 2018		1,172,707	$	2.23	$	1.09		8.72

Options granted		890,000		1.07		0.51		9.92
Expired		—		—		—		—
Forfeited options		40,890		3.85		1.59		8.04
Exercised		—		—		—		—

Outstanding at September 30, 2019		2,021,817	$	1.69	$	0.83		8.98
Unvested at September 30, 2019		810,000	$	1.64	$	0.77		9.60

	Number of Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Contractual Life (Years)
Outstanding at January 1, 2019		1,172,707		$	1.85	$	1.09		8.72
Granted		890,000			1.07		0.52		9.66
Expired		-			-		-		-
Forfeited/Cancelled		(40,890	)		3.85		1.59		8.04
Exercised		-			-		-		-
Outstanding at December 31, 2019		2,021,817		$	1.69	$	0.83		8.73
Granted		150,000			8.14		4.70		7.30
Expired		-			-		-		-
Forfeited/Cancelled		-			-		-		-
Exercised		(420,289	)		1.53		0.79		7.62
Outstanding at June 30, 2020		1,751,528		$	2.28	$	1.21		8.50

	Warrants Outstanding		Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Contractual Life (years)
Outstanding at January 1, 2018		706,262		3.27		1.48		4.22
Warrants issued		50,000		2.00		1.22		5.00
Expired		—		—		—		—
Forfeited warrants		—		—		—		—
Exercised		272,727		0.64		0.54		3.64
Outstanding at December 31, 2018		483,535	$	4.92	$	1.99		3.29

Warrants issued		470,000		0.48		0.08		4.59
Expired		—		—		—		—
Forfeited warrants		—		—		—		—
Exercised		—		—		—		—

Outstanding at September 30, 2019		953,535	$	2.73	$	1.05		3.55

	Number of Warrants			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Contractual Life (Years)
Outstanding at January 1, 2019		483,535		$	4.92	$	1.99		3.29
Granted		500,000			1.53		1.46		5.00
Expired		-			-		-		-
Forfeited/Cancelled		-			-		-		-
Exercised		-			-		-		-
Outstanding at December 31, 2019		983,535		$	1.44	$	1.03		3.34
Granted		20,000			16.49		15.19		5.00
Expired		-			-		-		-
Forfeited/Cancelled		-			-		-		-
Exercised		(894,445	)		1.37		1.05		2.80
Outstanding at June 30, 2020		109,090		$	2.06	$	1.17		3.62

		Outstanding						Exercisable
Range of Exercise Prices		Number Outstanding		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price				Weighted Average Exercise Price
$	0.01-1.10		1,511,372		7.95	$	0.73		984,705	$	0.53
	2.00-3.85		1,055,445		8.12		2.54		772,112		2.51
	5.10-7.20		408,535		2.34		5.46		408,535		5.46
$	0.01-7.20		2,975,352		7.24	$	2.02		2,165,352	$	2.16

Year Ending December 31,
2020	$	198,148
2021		234,149
2022		35,998
Total	$	468,295

Year Ending December 31,
2020 (remainder)	$	172,950
2021		345,900
2022		345,900
2023		345,900
2024		57,653
Total lease payments	$	1,268,303

●	~~our ability complete capital raising transactions to fund continuing operations;~~
●	~~our ability to develop and commercialize new and improved products and services;~~
●	~~market acceptance of any products that may be approved for commercialization;~~
●	~~our ability to protect our intellectual property rights;~~
●	~~the impact of any infringement actions or other litigation brought against us;~~
●	~~competition from other providers and products;~~
●	~~the results of clinical trials and the regulatory approval process;~~
●	~~the results of clinical trials and the regulatory approval process;~~
●	~~changes in government regulation;~~
●	~~and other factors relating to our industry, our operations and results of operations.~~

	●	the results of clinical trials and the regulatory approval process;

	●	market acceptance of any products that may be approved for commercialization;

	●	our ability to protect our intellectual property rights;

	●	the impact of any infringement actions or other litigation brought against us;

	●	competition from other providers and products;

	●	our ability to develop and commercialize new and improved products and services;

	●	changes in government regulation; and

	●	other factors (including the risks contained in the section entitled “Risk Factors” in other documents we file with the SEC) relating to our industry, our operations and results of operations.

Profit Level	Co-Diagnostics, Inc. Share			Synbiotics Share

Up to $1,000,000		50	%		50	%
$1,000,000-$2,000,000		60	%		40	%
$2,000,000-$3,000,000		70	%		30	%
Above $3,000,000		80	%		20	%

Tuberculosis			10,400,000
Multi-drug resistant Tuberculosis			580,000
Zika			324,000,000
Hepatitis B			240,000,000
Hepatitis C			130,000,000
HIV			36,700,000
Malaria			214,000,000
Sexually Transmitted Illnesses			357,000,000
Human papilloma virus			291,000,000
Dengue			390,000,000
Total Annual Tests			1,993,680,000

	●	*Affordability:* Lower-cost test kits and low-cost MDx Device.

	●	*Flexibility:* Our tests have been designed to run on many vendors’ DNA diagnostic testing machines. These tests are particularly well suited to the new generation of “lab-on-a-chip” and “point-of-care” (“LOC” and “POC”), highly portable analysis machinery for field, clinic and office applications.

	●	Speed: We believe our rapid assay design system software provides shorter time to product release. This has been demonstrated with the conception, design, product manufacture, clinical verification and submission for a CE Mark for our Logix Smart coronavirus disease (COVID-19) test being approximately 30 days.

	●	*Accuracy*: We believe our tests are more sensitive and specific than competitors’ and can detect more strains of viruses.

	●	Exclusivity: We own all patents and all intellectual property used in preparation of our tests.

	●	*Personalized Medicine:* We project that rising health care costs in developed and developing nations will increasingly require that health care systems be patient specific to eliminate waste, misdiagnoses, and ineffectiveness. We believe a critical component will be accurate, more affordable DNA/RNA-based diagnostics, which we plan to offer.

	●	Low-cost Provider: We plan to keep our overhead low. Our platform technology obviates the need to pay patent royalties typically required of our competitors which use patented test platforms to design their tests.

	●	Worldwide Footprint: With a dynamic technology that encompasses markets worldwide, we anticipate that we can identify the best target markets, not only in highly burden developing countries (HBDC’s) but also in developed nations.

	●	Growth Industry Category: We believe that DNA/RNA testing is the fastest-growing segment of in-vitro diagnostic testing.

	●	Combination Product Offering: Our ultra-sensitive tests can be a well-designed match for a new generation of handheld and other small point-of-care (POC) devices now entering the market. Used together, these affordable tests and devices may revolutionize the molecular diagnostics industry in cost, speed of test results and simplification.

	●	*Multi-plexing:* Our existing multiplexed tests demonstrate that our CoPrimer designed tests are able to test for multiple targets in the same sample without the distortion caused by false negatives and false positives that generally occur in multiplexed tests.

	●	On January 30, 2019, we entered into a securities purchase agreement with investors, whereby the investors purchased from the Company an aggregate of 30,000 shares of Series A Convertible Preferred Stock of the Company for an aggregate purchase price of $3,000,000. The purchase price was paid by the investors with $1 million in cash and the conversion of a $2 million promissory note issued by the Company to one of the investors. All of the preferred shares have been converted to common stock.

	●	On February 4, 2019, we completed the sale of an aggregate of 3,925,716 shares of common stock, at a purchase price of $1.40 per share in a registered direct offering pursuant the Shelf Registration Statement. The aggregate gross proceeds for the sale of the shares were $5,496,002 and we received net proceeds after offering costs of $4,996,322.

	●	In January 2020, we sold an aggregate of 3,448,278 shares of common stock to institutional investors for $1.45 per share for gross proceeds of approximately $5 million pursuant to a shelf-registration statement on Form S-3 (File No: 333-226835) declared effective by the SEC on September 7, 2018 (the “Shelf Registration Statement”).

	●	On February 10, 2020, the Company entered into securities purchase agreements with certain institutional investors pursuant to which such investors purchased an aggregate of 3,324,676 shares of common stock at a purchase price of $ 3.08 per share in a registered direct offering pursuant to the Shelf Registration Statement. The aggregate gross proceeds for the sale of the shares were approximately $10.2 million. The closing of the offering occurred on or about February 13, 2020.

	●	On February 28, 2020, the Company entered into securities purchase agreements with certain institutional investors pursuant to which such investors purchased an aggregate of 470,000 shares of common stock at a purchase price of $9.00 per share in a registered direct offering pursuant to the Shelf Registration Statement. The aggregate gross proceeds for the sale of the shares were approximately $4 million. The closing of the offering occurred on or about February 28, 2020.

	●	On March 6, 2020, we received $50,000 in gross proceeds from the exercise of a warrant for 25,000 shares of common stock for $2.00 per share. During the three months ending June 30, 2020, we received $863,465 from the exercise of warrants and stock options.

	●	We generated $13,939,816 in net income during the six months ending June 30, 2020 to fund our operations.

	●	Our ability to develop additional infectious disease diagnostic tests for which there is a commercial market.
	●	our ability to convince our potential customers of the advantages and economic value of our tests over competing technologies and diagnostic tests;
	●	the breadth of our test menu relative to competitors;
	●	changes to policies, procedures or currently accepted best practices in clinical diagnostic testing;
	●	the extent and success of our marketing and sales efforts; and
	●	our ability to manufacture in quantity our commercial diagnostic tests and meet demand in a timely fashion.

	●	sales of our common stock by our shareholders, executives, and directors;
	●	our ability to enter new markets;
	●	actual or un-anticipated fluctuations in our annual and quarterly financial results;
	●	our ability to obtain financings to continue and expand our commercial activities, expand our manufacturing operations, conduct research and development activities including, but not limited to, human clinical trials, and other business activities;
	●	our ability to secure resources and the necessary personnel to continue and expand our commercial activities, develop additional diagnostic tests, conduct clinical trials and gain approval for our diagnostic tests on our desired schedule;
	●	commencement, enrollment or results of our clinical trials of our diagnostic tests or any future clinical trials we may conduct;
	●	changes in the development status of our diagnostic tests;
	●	any delays or adverse developments or perceived adverse developments with respect to review by the FDA or other similar foreign regulatory authorities of our planned clinical trials;
	●	any delay in our submission for studies or test approvals or adverse regulatory decisions, including failure to receive regulatory approval for our diagnostic tests;
	●	our announcements or our competitors’ announcements regarding new tests, enhancements, significant contracts, acquisitions or strategic investments;
	●	failures to meet external expectations or management guidance;
	●	changes in our capital structure or dividend policy, including as a result of future issuances of securities and sales of large blocks of common stock by our shareholders;
	●	announcements and events surrounding financing efforts, including debt and equity securities;
	●	competition from existing technologies and diagnostic tests or new technologies and diagnostic tests that may emerge;
	●	announcements of acquisitions, partnerships, collaborations, joint ventures, new diagnostic tests, capital commitments, or other events by us or our competitors;
	●	changes in general economic, political and market conditions in any of the regions in which we conduct our business;
	●	changes in industry conditions or perceptions;
	●	changes in valuations of similar companies or groups of companies;
	●	analyst research reports, recommendations and changes in recommendations, price targets and withdrawals of coverage;
	●	departures and additions of key personnel;
	●	disputes and litigations related to intellectual properties, proprietary rights, and contractual obligations;
	●	changes in applicable laws, rules, regulations, or accounting practices and other dynamics;
	●	actions taken by our principal shareholders and release or expiry of lockup or other transfer restrictions; and
	●	other events or factors, many of which may be out of our control.

	●	authorize the issuance of “blank check” preferred stock that could be issued by our board of directors in response to a takeover attempt;

	●	provide that vacancies on our board of directors, including newly created directorships, may be filled only by a majority vote of directors then in office, except a vacancy occurring by reason of the removal of a director without cause shall be filled by vote of the shareholders; and

	●	limit who may call special meetings of shareholders.

	●	a limited availability of market quotations for our securities;

	●	reduced liquidity with respect to our securities;

	●	a determination that our shares of common stock are “penny stock” which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;

	●	a limited amount of news and analyst coverage for our company; and

	●	decreased ability to issue additional securities or obtain additional financing in the future.

●	On April 1, 2020, we issued a warrant to acquire up to 20,000 shares of our common stock at an exercise price of $1.40. the warrant was issued to a consultant pursuant to our agreement with the consultant. The warrant has a five-year life.

●	On June 30, 2020, we issued an aggregate of 9,689 shares of our common stock for services rendered pursuant to consulting agreements.

●	In June 2020, we issued 110,000 shares of stock pursuant to the exercise of warrants at an exercise price of $2.00 to three individuals and one limited liability company.

Exhibit Number		~~Number~~ Description

31.1*		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File

	CO-DIAGNOSTICS, INC.

Date: November ~~12, 2019~~3, 2020	By:	/s/ Dwight H. Egan
	Name:	Dwight H. Egan
	~~Its:~~Title:	President and Chief Executive Officer (Principal Executive Officer)

Date: November ~~12, 2019~~3, 2020	By:	/s/ Reed LL. Benson
	Name:	Reed LL. Benson
	~~Its:~~Title:	Chief Financial Officer (Principal Financial and Accounting Officer)